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The bacteriological confirmation of tuberculosis in children is challenging. The current diagnostic gold 
standard, liquid culture of respiratory specimens, has low sensitivity in paucibacillary paediatric 
tuberculosis, and sputum collection in young children is relatively invasive and resource-intensive. 
Stool is easy to collect and may contain mycobacterial deoxyribonucleic acid (DNA) from swallowed 
sputum. However, the performance of polymerase chain reaction (PCR) assays, including Xpert 
MTB/RIF and HAIN FluoroType may be affected by PCR inhibition from stool enzymes and by 
instrument failure due to particulate matter blocking filters.  
In this study, we aimed to evaluate the diagnostic performance of stool specimens using a variety of 
stool pre-processing steps, including decontamination and lyophilisation; as well as various DNA 
extraction and molecular detection protocols.  
This study formed part of a larger prospective study involving children with suspected intrathoracic 
tuberculosis where up to 6 respiratory specimens were collected. Stool specimens were collected at 
enrolment where one portion was tested by a direct Xpert MTB/RIF protocol; the second portion was 
frozen for lyophilisation and/or DNA extraction protocols followed by PCR-based molecular detection. 
DNA was extracted from stools using either a manual commercial stool or soil kit. Extracted DNA was 
tested for the presence of mycobacterial DNA using the Xpert MTB/RIF cartridge according to standard 
manufacturer’s protocol and/or a modified “Tube Fill” protocol; and/or the HAIN FluoroType® MTB 
assay. The results were compared to a composite reference standard and a secondary reference 
standard (first respiratory culture), which was a better reflection of true performance in our setting. 
Our results indicate that the standard and Tube Fill Xpert MTB/RIF protocols, as well as the FluoroType 
MTB detection platforms are able to detect mycobacterial DNA from stool specimens. The Xpert 
MTB/RIF performed directly on decontaminated stool specimens was found to have the best 
diagnostic accuracy with sensitivities of 45.8% - 47.1% and specificities of 97.8% - 98.2%. This method 
was also found to have the lowest indeterminate rate of 3.4% - 10.3%. The other protocols 
investigated displayed unacceptable sensitivity and specificity combinations with high rates of 
indeterminate results. The high indeterminate rates were concerning and further optimisation and 
method simplification are required to propose stool as a non-invasive specimen type for the rapid 
confirmation of TB in children. 





Die bakteriologiese bevestiging van tuberkulose in kinders is uitdagend. Kultuur van die organisme, 
Mycobacterium tuberculosis, is die huidige goue-standaardtoets vir diagnose van tuberkulose. 
Ongelukkig is die kultuur van respiratoriese monsters in pediatriese pasiënte vermoeilik, aangesien 
die laer organismelading van pediatriese tuberkulose en die probleme met sputum versameling in 
jong kinders. Ontlasting (stoelgang) is maklik om te versamel en kan moontlik mikobakteriële 
deoksiribonukleïensuur (DNS) bevat vanaf die ingeslukte sputum. Die sukses van die polymerase 
ketting reaksie (PKR)-gebaseerde toetse, insluitend die Xpert MTB/RIF en die HAIN FluoroType kan 
egter nadelig beinvloed word deur PKR-inhibeerders teenwoordig in stoelgang (bv. ensieme), asook 
apparaat wanfunksionering as gevolg van stoelgang restes wat die filtreerders blok. 
Die doel van hierdie studie was om die diagnostiese benut van stoelgang as monstertipe vir die 
diagnose van tuberkulose te bepaal. Verskeie stoelgangs voorbereiding stappe, insluitend 
dekontaminasie en vriesdroging; asook verskeie DNS ekstraksie en molekulêre opsporingsmetodes is 
ondersoek. 
Die studie was deel van ‘n omvattende studie wat tot en met 6 respiratoriese monsters van kinders 
met vermoede pulmonale tuberkulose geneem het. Vir die doel van ons studie, is stoelgang monsters 
aan die begin van die studie versamel, en een porsie is deurmiddel van ‘n Xpert MTB/RIF getoets en ŉ 
tweede porsie is gevries vir latere vriesdroging gevolg deur DNS ekstraksie en PKR-gebaseerde 
molekulêre opsporing. 
DNS is geëkstraheer vanaf stoelgang monsters deur die gebruik van ŉ geoutomatiseerde kommersiële 
stoelgang of grond ekstraksie kit. Geëkstraheerde DNS is getoets vir die teenwoordigheid van 
mikobakteriële DNS deur gebruik te maak die Xpert MTB/RIF toets volgens die standaard protokol as 
ook ‘n aangepasde “Tube Fill” tegniek. Die Hain Fluorotype® MTB metode is ook ondersoek. Uitslae 
van die verskeie metodes is vergelyk met ‘n saamgestelde verwysingstandaard asook ‘n sekondêre 
verwysingstandaard (die eerste respiratoriese monster), wat ‘n beter besinning is van wat in praktyk 
in ons omgewing gebeur.  
Die studieresultate toon aan dat die standaard en “Tube Fill” Xpert MTB/RIF protokole, asook die HAIN 
FluoroType MTB deteksie platvorm wel mikobakteriële DNS vanaf stoelgang monsters kan opspoor. 
Die Xpert MTB/RIF gedoen op gedekontamineerde stoelgang het die beste sensitiwiteit (45.8% - 
47.1%) en spesifisiteit (97.8% - 98.2%) opgelewer met ‘n onbepaaldheids persentasie van 3.4% - 
10.3%. Die sensitiwiteit en spesifisiteit van elk van die ander protokole was nie belowend nie, en die 
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metodes het ook hoë onpebaaldheids syfers getoon. Die hoeveelheid monsters wat nie ‘n resultaat 
kon oplewer nie was kommerwekkend en verg verdere ondersoek om die tegnieke te verbeter en te 
vereenvoudig. Verdere studies is dus nodig voor stoelgang as ‘n nie-indringende monstertipe vir die 
spoedige bevestiging van tuberkulose in kinders voorgestel kan word.  
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Despite being one of the oldest infectious diseases affecting human kind, tuberculosis (TB) continues 
to infect millions of individuals every year, exposing those infected to the risk of progression to active 
TB disease. Although TB is preventable and treatable, complex socio-economic and health-related 
factors interact to fuel the ongoing global TB epidemic. The World Health Organisation (WHO) 
estimates that in 2015 there were 10.4 million new TB cases diagnosed worldwide of which 1 million 
(10%) were children. The six countries that accounted for the majority (60%) of new cases were India, 
Indonesia, China, Nigeria, Pakistan and South Africa (1).  
Delayed diagnosis of TB and poor implementation and management of the DOTS (Direct Observed 
Treatment Short-course) programme (2) contribute to the high morbidity and mortality of TB, and 
promote the emergence and spread of drug resistance in communities. Multi-drug resistant TB (MDR-
TB) (3) is characterised by resistance to rifampicin (RIF) and isoniazid (INH), 2 of the critical first line 
agents. Further resistance can lead to extensively drug resistant (XDR) TB (4), which is resistant to RIF, 
INH, a fluoroquinolone and an aminoglycoside; and eventually resistance to all known TB drugs 
(Totally drug-resistant TB (TDR-TB)) (5). 
In 2015, South Africa had one of the highest TB incidence rates on the continent and globally, with an 
estimated total incidence of 834 and 37 per 100 000 population for TB and MDR-TB respectively (1). 
A further concern in Sub-Saharan Africa, South Africa in particular, is the high rate of human 
immunodeficiency virus (HIV) and TB co-infection. It is estimated that 6.19 million individuals in South 
Africa are infected with HIV, of whom 0.26 million are co-infected with TB (1). HIV infection results in 
dysfunction of cellular immunity, which is the human body’s primary mechanism for containment of 
TB infection. HIV co-infection also complicates TB diagnosis, as described in section 1.2. There were 
an estimated 1.4 million deaths from TB in 2015 and an additional 0.4 million from TB among people 
living with HIV. In children, there were an estimated 0.17 million deaths from TB and 0.04 million 
deaths among HIV-infected children. Despite the decline in TB deaths from 2000 – 2015 by 22%, TB 
remains one of the top 10 causes of death worldwide (1). 
Stellenbosch University  https://scholar.sun.ac.za
 2 
 
High TB-burden regions are often poorly resourced: limited access to healthcare and health education 
may lead to a low awareness of TB symptoms (6). Stigma towards infected individuals is also a 
widespread cause of delayed diagnosis and treatment, with patients avoiding reporting of symptoms 
(7). A definitive diagnosis of TB depends on laboratory confirmation, but healthcare services are often 
poorly managed (8) and current diagnostic methods are suboptimal due to poor sensitivity and long 
turnaround time to results, particularly in high-risk populations such as HIV-infected individuals and 
children. The low bacillary load in HIV-infected individuals and in children translates into low sensitivity 
of smear microscopy, culture and molecular detection tests. In addition, diagnosis is further 
complicated by the difficulty in collecting high quality specimens for testing in sputum-scarce adults 
and in young children. Diagnostic delay leads to increased morbidity and mortality from TB, along with 
increased risk of spreading the disease in the community.  
 
1.2 Tuberculosis disease 
 
TB disease is caused by a group of closely related mycobacteria collectively classified as 
Mycobacterium tuberculosis complex (MTBC). The complex consists of M. bovis, M. africanum, M. 
microti, M. canetti and, the most prevalent, M. tuberculosis (MTB). The causative organisms, MTB, are 
rod-shaped aerobic bacteria that possess a mycolic acid-rich cell wall structure and are classified as 
non-spore forming, strictly aerobic acid-fast bacilli (AFB). The exceptional lipid structure of the cell 
wall provides an extensive protective barrier against antibiotics and the cellular defence mechanisms 
of the host (9). MTB is an airborne pathogen that can easily spread from person to person by the 
inhalation of small droplet nuclei (1-5 µm in diameter) containing viable MTB bacilli (10). These 
infectious droplet nuclei can enter the air when a person with active pulmonary tuberculosis (PTB) 
coughs, sneezes, or during aerosolisation of respiratory secretions during specimen collection (e.g. 
during sputum induction). The risk of infection is dependent on a variety of factors such as the 
mycobacterial load (smear positivity) of the source case, the relative proximity of individuals, indoor 
ventilation and the duration of exposure (11). The nuclei droplets are small enough to enter into the 
alveoli where the mycobacteria can either be cleared by the immune system, remain dormant (latent 
TB infection) or systematically cause active pulmonary disease within the alveolar macrophage that 
ingests it (12). Once MTB is ingested by a macrophage, the bacilli release proteins that interact and 
prevent fusion with the lysosome and MTB can thus proliferate creating a localised (primary) infection. 
A few weeks after a primary infection has occurred, other immune cells are attracted to the infected 
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area, and, through cell-mediated immunity, create a granuloma. The tissue located in the centre of 
the granuloma dies during a process called caseous necrosis and forms scar tissue known as a Ranke-
complex, which may be visible on a chest radiograph (CXR). The immune system attempts to isolate 
the dead tissue but the MTB bacilli within can remain viable. When the immune system becomes 
compromised by old age, HIV-infection, malnutrition or the use of immunosuppressant drugs, the 
bacilli can re-activate and spread through the lung causing the host to release more inflammatory 
mediators, thereby resulting in an increase in caseous necrosis. This widespread necrosis leads to 
cavity formation within the lung. MTB can also proliferate and disseminate throughout the lung to 
other organs via the blood stream or lymphatic system, resulting in extrapulmonary or miliary TB 
disease (13). 
Several factors contribute to the complexity of the clinical manifestations of TB, including age, immune 
status, nutrition, comorbidity, genetic factors, virulence of the organism and the site of disease. The 
symptoms of adult-type TB are usually systematic in commencement and the duration can vary from 
weeks to months. The most common clinical symptoms include prolonged cough, fever, night sweats, 
weight loss and haemoptysis (14). TB presentation is frequently atypical in HIV-infected individuals. 
HIV infection is associated with increased risk of active TB following new or latent TB infection and of 
TB recurrence, compared to HIV-uninfected individuals (15). HIV-associated TB is less likely to present 
the characteristic clinical and radiological findings usually associated with active TB and is often  
sputum smear microscopy negative resulting in delayed diagnosis and treatment (16).  
The clinical presentation of TB in children is frequently non-specific, although older children may show 
signs and symptoms similar to adult-type TB (17). However, the greatest risk for TB-related morbidity 
and mortality remains in very young children as they are at higher risk of developing active TB after 
primary infection. In this population group, TB symptoms are non-specific and overlap with many 
other conditions, especially in HIV-infected children. The most common general symptoms are fever, 
lethargy and weight loss or poor growth, while the most common organ-specific symptom is persistent 
cough lasting more than 2 weeks (18). However, in children younger than 3 years, the presentation 
may be more acute (19). 
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1.3 Diagnosis in children in South Africa 
 
A definite diagnosis of TB is challenging in children due to the paucibacillary nature of the disease. 
Sputum smear microscopy provides confirmation of AFB in only 10 - 15% of children with TB disease. 
The gold standard, culture-based method, is more sensitive than smear microscopy (30 - 40%), but 
most children treated for TB are culture negative (i.e. clinically diagnosed) (20,21). In children, PTB can 
be confidently diagnosed in a proportion who present with typical symptoms, suggestive CXR and 
evidence of TB infection (see immunological tests in section 1.3.3). However, in most children, not all 
factors may be present. In young children who are unable to expectorate spontaneously, the collection 
of adequate respiratory specimens is challenging and requires relatively invasive and resource-
intensive procedures. 
 
1.3.1 Clinical investigations 
 
In non-endemic regions, a positive tuberculin skin test (TST), a suggestive CXR and exposure to a 
confirmed known source is often sufficient to diagnose TB disease in children. In endemic regions, 
however, community exposure to TB is much higher and these methods show limited value in 
diagnosing and differentiating between active and latent TB disease. Symptom-based approaches to 
diagnose childhood TB have poor diagnostic accuracy, as the disease spectrum is often broad and the 
non-specific symptoms displayed by children with TB could be due to a variety of other unrelated 
illnesses. Well-defined symptoms such as persistent non-remitting cough or wheezing, failure to thrive 
and fatigue or reduced playfulness were found to have a sensitivity of 82.3% for diagnosing TB in 
children >3 years of age, but performed poorly in young and HIV-infected children (18). Due to the 
limitations of the different diagnostic modalities and low sensitivity of bacteriological tests in children, 
various scoring methods have been developed to diagnose active TB. However, these scoring systems 
have not been validated and vary widely in performance depending on setting and patient population 
(22).  
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1.3.2 Radiological methods 
 
Chest radiography is widely used to aid in the diagnosis of childhood TB, where radiology services are 
available and affordable. Chest radiographs are useful to diagnose typical manifestations of TB such 
as miliary TB and effusion. However, radiography is highly operator dependant and the interpretation 
has high inter-reader variability (23), especially to detect hilar nodes, which is the most common 
manifestation of TB in children. In addition, non-TB conditions can present very similar radiographic 
findings. This is especially the case in children with HIV-associated lung disease. The interpretation of 
results remains subjective and usually requires one or more experienced clinicians to accurately and 
correctly interpret results (24). In children, computed tomography is useful for detecting intrathoracic 
lymph nodes, airway compression and differentiating TB from other conditions (25). However, this 
diagnostic modality is unaffordable for most low-resource settings. Radiographic tests cannot be used 
as an independent diagnostic tool due variable disease presentation, interpretation of results and the 
similarity of patterns associated with other non-TB diseases (20).   
 
1.3.3 Immunological methods 
 
Immune based assays can be used to detect antibodies, antigens and immune complexes. Serological 
assays for TB have demonstrated very poor diagnostic utility and the WHO has issued strong 
recommendations against the commercial use of serodiagnostic tests for diagnosis of active TB (26). 
Serological assays are mainly used to demonstrate exposure to TB although in high endemic areas the 
need remains for the clear differentiation between active and latent TB (20). Tests of infection in 
current use are the Mantoux TST and Interferon Gamma Release Assays (IGRAs). 
TST uses a purified protein derivative (PPD) derived from tuberculin, which is injected under the skin 
(intradermally). If the PPD is recognised by the immune system, it induces a delayed T-cell mediated 
reaction in most infected individuals. The TST is evaluated 48-72 hours after administration. Recently 
infected individuals may be non-reactive for 2-8 weeks post infection. The TST cannot differentiate 
between TB infection and active TB disease. In addition, several factors can result in false positive 
results, such as infection with some species of non-tuberculous mycobacteria (NTM) and Bacille 
Calmette-Guerin (BCG) vaccination. False negative results can occur in individuals with a recent 
Stellenbosch University  https://scholar.sun.ac.za
 6 
 
primary infection, HIV-infected individuals, overwhelming TB infections, very young children and the 
incorrect administration and interpretation of the TST (27). 
Interferon Gamma Release Assays (IGRAs) determine the presence of TB infection by measuring the 
immune response to TB proteins ESAT-6 and CFP-10 (with or without TB 7.7) in whole blood. IGRAs do 
not differentiate between latent and active disease and additional tests are required to confirm TB 
disease. The tests are expensive compared to the TST although they do seem to perform better in HIV 
associated TB (28). 
 
1.3.4 Bacteriological methods 
 
The most common procedure to obtain swallowed sputum from infants and young children suspected 
of having TB is the aspiration of gastric contents, as young children are unable to spontaneously 
expectorate sputum (29). In our setting, it is recommended that at least two gastric aspirate (GA) 
specimens are collected on consecutive days (30) from patients who cannot expectorate, although 
guidelines from the WHO and Centres for Disease Control and Prevention (CDC) recommend 3 
consecutive GA specimens. GA specimens are usually collected early in the morning, before gastric 
emptying and following an overnight fast (31). Sputum induction, which does not require 
hospitalisation, and less invasive nasopharyngeal aspiration (NPA) have also been used successfully 
for TB diagnosis in community-based studies. Bacteriological detection from induced sputum (IS) may 
be comparable to that from GA specimens (32–34). NPA specimens are easier to collect than IS, but 
diagnostic performance appears inferior (35). The collection of multiple specimens of different types 
has been shown to result in higher bacteriological detection than the collection of numerous 
specimens of the same type (35). There are numerous bacteriological methods for the detection of 




Sputum smear microscopy is considered an inexpensive, rapid and relatively straightforward 
diagnostic test, especially in high TB-burden regions. However, sensitivity in children remains low with 
fewer than 20% of TB cases being smear-positive (36,37). Since its introduction in 1937 (38), 
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fluorescence microscopy has been widely used as a rapid detection method of acid fast bacilli. 
Fluorescence microscopy uses an acid-fast dye, usually Auramine O or Auramine-rhodamine, in 
combination with an intense light source such as a halogen, mercury vapour or light emitting diode 
(LED) lamp. The conventional Ziehl-Neelsen (ZN) staining is less sensitive than fluorescent staining for 
direct microscopy and is now generally used to detect the presence of AFB in positive cultures. Sputum 
concentration prior to microscopy also shows increased sensitivity (average 18%) over direct 
microscopy from unconcentrated sputum (39).  
AFB microscopy detects both viable and non-viable bacilli that have been stained and counterstained 
on a glass slide and involves the physical counting of bacilli to report results based on a 
WHO/International Union Against Tuberculosis and Lung Disease (IUATLD) grading system (40). Other 
Gram-negative bacteria, including Nocardia and Corynebacteria species may also stain positive, 
thereby affecting the specificity of the test. AFB microscopy can therefore not be used as a stand-
alone test to confirm a diagnosis of TB disease. Furthermore, the analytical sensitivity of microscopy 
is only ± 104 bacilli per millilitre and therefore many true positives are missed by microscopy alone. 
ZN stains are prepared from MGIT positive cultures. A smear of the culture is prepared on a glass 
microscope slide and is stained using a combination of carbol fuchsin (AFB stain), heat, acid alcohol 
(decolouriser) and methylene blue (counterstain) as per the procedure in Section 2.7.5. AFB stain red 
and the majority of MTBC strains form cord-like (serpentine) structures when viewed under a light 
microscope. Where no AFB are seen and/or where other micro-organisms are visible, samples are re-
decontaminated as per Section 2.7.1. Suspected false positives are eliminated according the NHLS TB 




Despite recent advances in molecular based detection platforms, the gold standard for MTB detection 
remains culture. The main benefit of a culture based system is the ability to perform multiple tests on 
a single isolate if required. 
TB culture includes the following aspects:  
1) inhibition of all bacteria other than mycobacteria (decontamination),  
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2) separating/releasing mycobacteria from the specimen e.g. thick mucus from respiratory 
specimens or solid organic cellular debris found in stool specimens (liquefaction or digestion); 
and;  
3) the growth of the mycobacteria for further diagnostic identification.  
The sodium hydroxide/N-acetyl-L-cysteine-sodium citrate (NaOH-NALC-Na citrate) method is 
recommended for decontamination of respiratory specimens. NALC is a mucolytic agent, while NaOH 
is a decontaminating agent at low (final) concentrations (1 - 1.5%) and Na-citrate acts as a stabilisation 
agent on the NALC. NaOH, however, remains toxic to contaminating microorganisms and 
mycobacteria at high concentrations or prolonged exposure and is neutralised by the addition of 
phosphate buffered saline (PBS).  
The growth of mycobacteria is achieved by using the Bactec MGIT 960 system (Becton Dickinson 
diagnostic systems, New Jersey, USA) where the sediment obtained after decontamination and 
digestion is inoculated into a Mycobacteria Growth Indicator Tube (MGIT). The Middlebrook 7H9 broth 
inside the MGIT is nutrient rich and in combination with an added growth supplement, oleic acid 
albumin dextrose catalase complex (OADC), and antibiotic mixture, Polymyxin B, Amphotericin B, 
Nalidixic acid, Trimethoprim and Azlocillin (PANTA), provides a suitable environment for the culture 
of mycobacteria.  Detection of mycobacterial growth is based on a fluorescent indicator compound 
embedded within the MGIT’s silicon rubber base which is oxygen sensitive. As bacteria metabolise the 
available (free) oxygen in the MGIT, the carbon dioxide levels increase and the fluorescence levels rise 
as the fluorescent indicator is no longer inhibited by the oxygen, resulting in a positive signal. The 
turbidity of the growth can be visually assessed: mycobacteria will be granular or flaky in appearance 
and not very turbid, whereas bacterial growth is highly turbid. The time to detection (TTD) of adequate 
fluorescence (average of 8 to 14 days in this setting), usually between 105 or 106 colony forming unit 
(CFU) per millilitre (41), is recorded by the on-board software and provides an indication of the initial 
bacterial concentration of the original specimen. The average TTD is dependent on the sample type, 
contamination rates and is often longer for paediatric TB specimens due to the low bacillary load. In 
most settings, once a positive signal (when the growth unit reaches 400) is observed (42), confirmation 
of positivity is done by ZN microscopy (Section 1.3.4) and inoculation on a blood agar plate (BAP) to 
detect contamination. A rapid antigen identification test, such as the MPT64 lateral flow 
immunochromatographic assay (43) is used to confirm the presence of MTB complex in a culture (38) 
when no further drug susceptibility testing (DST) is requested or to confirm an NTM or BCG infection 
(Appendix G). 
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It is recommended to use more than one type of selective media to maximise the recovery of MTB 
from clinical specimens. This is most commonly additional solid culture medium, usually an egg-based 
medium for example an LJ slope, Ogawa or Middlebrook (7H10, 7H11) media. However, in our setting, 
solid culture media are not used to culture TB specimens.  
There is usually a diagnostic delay associated with all culture-based methods for the detection of drug-
resistant paucibacillary TB: the delays could be patient-related (late presentation of symptoms) or 
doctor-related (failure to consider a diagnosis of tuberculosis). Studies on the exact impact of these 
delays on paediatric TB diagnosis are limited although some evidence suggests that they adversely 
impact the time to appropriate treatment (44) and could affect clinical outcomes (45). 
 
c) Phenotypic drug susceptibility testing (DST) 
 
Phenotypic DST typically requires a positive culture (indirect method), where growth (solid) or a 
cellular suspension of MTB growth (liquid) is inoculated on solid media or in liquid (broth) media 
containing a pre-determined concentration of a targeted antimicrobial agent. The traditional DST 
method, the agar proportion method, uses a homogenous suspension of confirmed TB positive cells 
that are inoculated onto calculated antimicrobial agent-containing and antimicrobial agent-free 
(control) solid media agar plates (Middlebrook). The ratio of CFUs (antimicrobial agent-containing vs. 
antimicrobial agent-free solid media) determines the susceptibility or the resistance of the isolate to 
a specific antimicrobial agent.  
The more commonly used method is the broth based or liquid culture proportion method using either 
the BACTEC460 (Becton Dickinson diagnostic systems, New Jersey, USA) or the MGIT960 system. 
Similarly, a confirmed TB positive cellular suspension is inoculated into a calculated antimicrobial 
agent-containing and antimicrobial agent-free (control) broth tube. The cellular suspension must be 
tested within 1-5 days of instrument positivity for MGIT cultures; cultures that have been positive for 
more than 5 days must first be subcultured into a fresh MGIT prior to phenotypic DST. The positive 
cellular suspension (0.5 ml) is added to 5 MGIT tubes containing 0.8 ml MGIT SIRE supplement as well 
as 0.1 ml of the different drugs tested for; the growth control (GC) tube will not have any drug added. 
The 5 tubes are then incubated in the MGIT 960 instrument that monitors the susceptibility test set. 
The instrument interprets the results when the growth unit in the GC tube reaches 400 (within 4-13 
days). If the GC tube becomes positive within 4 days or remains negative after 13 days of incubation, 
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the test is repeated by either increasing or decreasing the dilution of the original culture, respectively 
(41). Following incubation (4-21 days), a comparison of the fluorescence emitted by both tubes 
concludes whether a specimen is susceptible (the growth unit of the drug-containing tube is less than 
100) or resistant (the growth unit of the drug-containing tube is more than or equal to 100) to a specific 
antimicrobial agent. Each antimicrobial agent has a precise critical concentration and increased 
microbial growth, solid or liquid based, at this concentration, when compared to the same isolate 
diluted to a defined concentration in the absence of the antimicrobial agent, will be considered 
resistant (41).  
 
1.3.5 Genotypic methods 
 
In the South African public healthcare system, two different PCR-based methods are available for the 
diagnosis of TB and associated drug resistance: the GeneXpert MTB/RIF assay (Xpert; Cepheid, 
Sunnyvale USA) and the Genotype MTBDRplus and MTBDRsl assays (Hain Lifescience GmbH, Nehren, 
Germany). The Xpert MTB/RIF assay is a WHO-recommended rapid (within 2 hours) diagnostic test for 
the detection of PTB and RIF resistance from primary clinical specimens from adults (since 2010) and 
children (since 2013). The Xpert assay is an automated diagnostic test and a semi-quantitative, nested 
real-time PCR used for the detection of MTB DNA. The assay is recommended for use in combination 
with other routine clinical and laboratory tests on patients with suspected TB with no, or less than 
three days of antituberculosis treatment (46). The Xpert assay targets the 81-base pair core region of 
the rpoB gene, which contains mutations associated with RIF resistance (detectable by 5 wild-type and 
3 mutation probes). The assay can be used on raw sputum specimens or concentrated sputum 
sediments from IS or expectorated (ES) sputa. Specimens are tested using disposable single-use 
cartridges and results are interpreted by the GeneXpert Dx software after testing on the GeneXpert 
instrument. The automated process also includes internal controls for sample processing (SPC) and a 
probe check (PCC). The SPC contains non-infectious spores and regulates the appropriate processing 
of target bacteria and monitors the presence of PCR inhibitors whilst the PCC ensures that there is 
sufficient reagent rehydration, PCR tubes are correctly filled, probes are checked and monitors the 
stability of the dye. The SPC should always be positive in the case of a negative Xpert MTB/RIF result; 
however, SPC may be negative in the event of a positive result due to competitive inhibition. If the 
internal control(s) fail, the test should be repeated if there is sufficient specimen volume remaining 
(47). 
Stellenbosch University  https://scholar.sun.ac.za
 11 
 
In children with pulmonary TB, the Xpert MTB/RIF assay has 36-44% increased sensitivity compared 
to smear microscopy; and sensitivity compared to culture is approximately 62% for expectorated 
sputum (ES), and 66% for both IS and GA (48). The Xpert MTB/RIF assay can also detect more than 
99.5% RIF resistance compared to phenotypic DST (49). The WHO also recommends the use of the 
Xpert MTB/RIF assay on some extrapulmonary specimens including cerebrospinal fluid (CSF), fine 
needle aspirates (FNA), pleural fluid and tissue specimens (47). The assay can be used directly on CSF, 
FNA and pleural fluid specimens or homogenised (PBS buffer) tissue biopsy specimens ground by a 
mortar or pestle, avoiding clumps of tissue being transferred to the cartridge. For extrapulmonary TB, 
especially in young children, culture is recommended for Xpert MTB/RIF negative specimens. It is 
recommended that low-volume CSF specimens from children are preferentially tested by Xpert rather 
than culture (47). For extrapulmonary specimens obtained from adults and children, the Xpert 
MTB/RIF assay demonstrated sensitivities of 84.9% for lymph node tissue/aspirates, 83.8% for gastric 
fluids, 81.2% for tissue specimens, 79.5% for CSF and 43.7% for pleural fluid, when compared to liquid 
culture (47).  
The second group of genotypic assays routinely used in the South African context are the Genotype 
MTBDRplus (version 2) and MTBDRsl assays (Hain Lifescience GmbH, Nehren, Germany). Both can be 
done directly from clinical specimens, usually if smear-positive, or on positive culture material (as for 
our setting) to determine genotypic RIF and INH susceptibilities or to confirm RIF resistance detected 
by the Xpert assay. The MTBDRplus assay simultaneously detects mutations associated with RIF 
resistance of the rpoB gene and INH resistance associated mutations of the katG (high level INH 
resistance) and inhA (low level INH resistance) genes. Mutations causing resistance can be detected 
in more than 98% of RIF resistant strains and 90% of INH resistant strains (50). 
The MTBDRsl assay is used for the detection of second-line antimicrobial susceptibility 
(fluoroquinolones and aminoglycosides) and is a useful tool to rapidly detect XDR-TB when used in 
combination with the MTBDRplus assay. The MTBDRsl assay (version 2.0) detects mutations in the 
gyrA and rrs genes determining susceptibility to the fluoroquinolones and the second-line injectable 
drugs kanamycin/amikacin respectively. Fluoroquinolone resistance caused by mutations in the gyrA 
gene accounts for 75 - 95% and aminoglycoside resistance caused by mutations in the rrs gene 
accounts for ~76% of resistance (51). The Xpert MTB/RIF assay, along with all other molecular based 
tests cannot be used to monitor treatment outcomes due to the detection of MTB DNA which could 
originate from either live or dead bacilli. There are limited data on the use of the MTBDRplus and 
MTBDRsl assays on extrapulmonary specimens as they were designed for direct sputum samples. 
Stellenbosch University  https://scholar.sun.ac.za
 12 
 
Other specimen types (Bronchoalveolar lavage - BAL, CSF or other body fluids) have not been 
comprehensively evaluated (52,53). 
 
1.4 Alternative specimen types 
 
The difficulty in obtaining representative specimens from young children and those unable to 
expectorate remains challenging and extrapulmonary sites may not always be accessible. Due to the 
difficulties in obtaining serial GA specimens, alternative specimen types for the detection of PTB 
include BAL, gastric fluid absorbed by a string, NPA and stool specimens, bone marrow and urine have 
also undergone evaluation for the diagnosis of TB when extrapulmonary TB is suspected (30).  
 
BAL specimens are obtained using flexible bronchoscopy, during which lavage fluid is flushed into the 
suspected diseased portion of the lung and is aspirated by suctioning. Bronchoscopy is invasive, 
expensive and requires specialised personnel and equipment. BAL specimens have shown to have a 
lower yield compared to GA and IS for TB culture (54,55) in children with uncomplicated PTB. More 
recently, BAL specimens showed an incremental diagnostic yield (compared to culture of routine 
respiratory samples) in a small subset of children with complicated intrathoracic TB using the Xpert 
MTB/RIF assay (56,57).  
NPA specimens are obtained by inserting a tube through the nostril into the nasopharynx after 
instillation of saline solution into the nose, followed by aspiration or expectoration of secretions from 
the lower respiratory tract. This method is considered minimally invasive and does not require a 
lengthy fasting period or hospitalisation. Early studies showed that the diagnostic yield from NPA was 
comparable to that of GA or IS specimens (54). Further studies showed the bacteriological yield to be 
lower compared to GA specimens (58,59).  Molecular detection in children with suspected PTB showed 
that the use of two NPAs for Xpert testing could be useful in settings where culture and IS are 
unavailable (35).  
The string test collection method uses an encapsulated absorbent nylon string that must be swallowed 
by an individual allowing it to enter the stomach. The latter half of the string remains fastened to the 
cheek and the string is recovered by gentle traction after 2-4 hours and placed in a saline buffer (60). 
The string test demonstrated the ability to successfully retrieve MTB from the stomach of sputum 
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scarce adults (61). In children the string test detection yields were shown to be comparable to IS 
although many children (16.1%) were unable to swallow the large capsule (60). 
FNA is considered minimally invasive and involves the use of a fine 23-gauge needle to obtain an 
aspiration from a lymph node for the diagnosis of tuberculous lymphadenitis, the most common form 
of extrapulmonary TB disease in children (26). Diagnostic yield from suspected TB lymph nodes is high 
on most modalities, including culture and Xpert (62). However, this procedure requires a lymph node 
to be visibly enlarged and highly trained clinical staff to complete the procedure (54).  
Bone marrow biopsy and aspiration for the diagnosis of extrapulmonary TB are infrequently used and 
typically reserved for situations where the clinical suspicion of disseminated TB is strong, all other less 
invasive tests were inconclusive or if a confirmed diagnosis would influence treatment decisions and 
patient outcomes (63).  
All the above-mentioned specimen collection methods are invasive, somewhat traumatic for children 
and usually require hospitalisation. For children, the ideal specimen would be one that can be 
collected easily and non-invasively. Urine and stool are examples of such specimens. 
Urine can be collected relatively easily from children using urine collection bags applied to the 
perineum or containers for children who are toilet trained. The detection of lipoarabinomannan (LAM) 
using immune-capture assays for diagnosing active TB from urine had been considered initially a 
potentially revolutionary tool for HIV-associated TB and was accelerated to commercial development. 
Subsequent larger studies failed to demonstrate adequate sensitivity under routine conditions from 
non-selective participants (64,65). Despite very limited and low-quality data from children, TB LAM 
lateral flow testing was recently accepted by WHO as a rule-in test for HIV-infected children only, but 
should be used in combination with other detection methods (66). The TB LAM test may only be used 
to assist the diagnosis in HIV positive children or adults with sign or symptoms of TB where they have 
a CD4 count of less than 100 cell/µl or if they are seriously ill with no CD4 count available (67).  
 
1.4.1 Stool specimens 
 
Stool specimens are easy to collect and can contain intact bacilli from swallowed sputum following 
the passage through the digestive tract (68,69). Stool contains many PCR inhibiting substances and 
contaminating bacteria and thus requires stringent decontamination procedures, which could in turn 
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also affect the viability of MTB and possibly degrade MTB DNA. The different decontamination 
methods used for the culture of stool specimens are outlined in Table 1.1 below. 
Most studies use the conventional NALC-NaOH Na-citrate decontamination method as described by 
Kent and Kubica in 1985 (70) for respiratory specimens or a variation of this protocol.  Due to the vast 
number of microorganisms found in stool specimens, finding the delicate balance between sufficient 
bacterial decontamination whilst not eliminating too many or all MTB bacilli remains challenging.  
Colenbunders et al (68) used three decontamination methods as summarised in Table 1.1 on adult 
stools and concluded that MTB are less likely to be isolated from patients with diarrhoea than without, 
most likely due to the dilution of organisms created by the increased water content. However, they 
did not compare the decontamination methods. Kokuto et al (71) used the conventional NALC-NaOH 
Na-citrate method, with a final NaOH concentration of 3%, to process 2 cm3 of adult stool specimens 
in MGIT and 2% Ogawa media. For MGIT and Ogawa culture, sensitivities and specificities were 31.9% 
and 100%; 21.4% and 100%, respectively. Contamination of MGIT culture was 14.0% as opposed to 
0% for Ogawa media. They concluded that the culturing of stool specimens for PTB detection was 
ineffective (71). 
Oberhelman et al (58) collected daily stool specimens from children over 2 days and showed that GA 
specimens were superior to stool specimens for MTB recovery in 15 culture confirmed cases. They 
suggest that the sensitivity of detection in stool specimens can be increased by culturing a larger 
volume of specimen if the decontamination and concentration process could be improved. 
El Khechine et al (72) filtered stool specimens using a faecal specimen filtration vial kit which they 
modified by the addition of a macro porous compress that has specific mesh openings and uniformly 
oriented fibres which ensured that mycobacterial cells were not trapped within the filter matrix. 
Specimens were decontaminated with 3 volumes of 1% chlorhexidine digluconate. They reported MTB 
culture detection in 14.9% of sputum specimens compared to 9.7% in stools. Stool culture 
demonstrated a sensitivity of 54.2% and specificity of 100% compared to any confirmed culture 
positive specimen. Similarly Donald et al (69) collected two stool specimens from each participant 
using the method of Allen et al (73), and both studies concluded that stools could be used in 
conjunction with sputum testing or as an alternative diagnostic specimen (Table 1.1) (69,74). 
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0.1 g Children Uninfected (59) 
3 methods* 3 methods* 
n = 59 LJ and Ogawa n = 4 7.0% 
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Not Stated Not stated Infected 
(68) 
n = 41 LJ and Ogawa n = 1 2.0% 
Not 
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suspension Not Stated Both (73) 









Not Stated Children Not Stated (69) 
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suspension Not Stated Both 
NALC/NaOH NA-
Citrate Equal volume n = 192 LJ n = 8 27.0% 
Not 





2-3 g Children Status unknown (76) 
NALC/NaOH 
Equal volume 
of 3% NaOH 
(final) 
n = 93 
MGIT n = 15 31.9% 100% 14.0% Active PTB 2 cm3 Adults Uninfected 
(71) 
Ogawa n = 12 21.4% 100% 0% Active PTB 2 cm3 Adults Uninfected 
*Three methods were used: a) method of Petroff b) the method of Beerwerth and Schurmann c) the method of Wilinsky and Rynearson modified by Portaels et al (73). 
** No volume specified only defined as “spoonful”
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Due to the varied and limited success of stool specimens for both solid and liquid culture-based 
testing, studies have implemented molecular detection techniques in an attempt to avoid the 
contaminating effect of the many microorganisms present in the stool. Molecular detection studies 
are summarised in Table 1.2 below. 
Cordova et al (77) collected pairs of stool specimens, from both HIV seronegative and seropositive 
adults (>17 years of age), prior to or within 2 weeks of treatment start date. They demonstrated that, 
heminested IS6110-PCR on stool is a useful method for rapid MTB detection with sensitivity and 
specificity similar to that of conventional sputum culture (Table 1.2)  (77). 
Wolf et al (78) used stool specimens stored for two years from culture confirmed cases in children. 
They showed that IS6110-PCR with Fast-DNA stool sample processing for diagnosing PTB had a 
sensitivity of 38% and specificity of 100% compared to culture of multiple specimens. They also 
showed that culture and PCR testing on duplicate specimens increased diagnostic sensitivity (Table 
1.2), suggesting that the mycobacterial load of paediatric specimens oscillates around the threshold 
of detection sensitivity of current testing platforms (78). 
Oberhelman et al showed that IS6110-PCR was more sensitive for detecting MTB in NPA and GA 
specimens than from stool specimens in children. They also found that several healthy controls were 
PCR positive suggesting false-positive results despite rigorous measures to prevent cross 
contamination. These results could also indicate that PCR may detect early, latent or asymptomatic 
TB disease. (59). 
Hilleman et al (28) tested decontaminated stool specimens from adults and children using the Xpert 
MTB/RIF assay, along with MGIT and Löwenstein-Jensen (LJ) cultures. Besides detecting MTB with 
100% sensitivity and 91.7% specificity compared to culture, stool Xpert also detected MTB in 21.7% of 
culture contaminated specimens (Table 1.2) (79).  
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populatiion Stool used Stool mass HIV 
Extraction 
method Reference 
Xpert MTB/RIF n = 23 100% (2/2) 91.7% 13.0% Stool culture confirmed 
Adults and 
children  Decontaminated Not Stated Not Stated 
Xpert 
MTB/RIF (79) 
Xpert MTB/RIF n = 93 85.7% (48/56) 100% 3.2% Active PTB Adults Pre-treated 2 cm
3 Uninfected Xpert MTB/RIF (71) 
Xpert MTB/RIF 














Children Raw and stored  0.5 g   Xpert MTB/RIF 
Xpert MTB/RIF n = 115 47.1% (8/17) 99.0% None 
Culture-






Xpert MTB/RIF n = 14 75.0% (3/4) 100% None 
Culture-






Xpert MTB/RIF n = 20 




MTB/RIF  (83) 
84.0% 95.0% 7.8% TB cases Children Raw  1.2 g  Xpert MTB/RIF 
*No volume specified only defined as “spoonful”
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In recent studies, Walters et al (82) demonstrated a stool Xpert MTB/RIF sensitivity of 75% in a small 
subset of children compared to culture confirmed cases, following homogenisation and concentration  
of the specimens. Marcy et al (80) demonstrated sensitivities of 47.1% -68.8% using homogenised, 
gauze filtered and concentrated stool specimens for Xpert MTB/RIF analysis compared to culture 
confirmed cases in HIV-infected children. They also stated that larger volumes of stool specimens led 
to clogging of the Xpert MTB/RIF filters. Similarly Banada et al (83) concluded that a larger volume of 
homogenised, glass wool filtered stool (1.2 g) did not perform better than the smaller weight (0.6 g) 
and demonstrated a lower specificity (95%). Kokuto et al (71) demonstrated overall sensitivity of 
85.7% with 100% specificity when testing pre-treated adult stool specimens on the Xpert MTB/RIF 
platform compared to active PTB cases. Their indeterminate rate was low at 3.2% (Table 1.2).  
Stool specimens have been successfully used for the culture and molecular detection of MTB and show 
some potential as a diagnostic specimen. The sensitivities and specificities for the methods (Table 1.1 
and Table 1.2) remain variable due to different stool preparation and processing methods, diverse 
patient populations and differences in the reference standard used. There is currently no gold 
standard method for processing of stool specimens for TB testing by culture or molecular methods. 
Given the limited data, all stool processing methods for culture need to be optimised for the detection 
of MTB from stool samples, and a balance between detection and contamination remains essential. 
Xpert MTB/RIF appears to perform better than heminested PCR assays to detect MTB DNA from stool 
specimens, particularly in children, but there is scope for improvement and optimization.  
In public sector hospitals in South Africa, TB culture of stool specimens may be requested if abdominal 
TB is suspected. Stool specimens of >1 g may be sent to the TB laboratory when no other respiratory 
specimens can be obtained from a patient or if abdominal TB is suspected. An AFB stain is prepared 
from a portion of the stool specimen, and, if smear-positive, the original specimen is decontaminated 
using the routine NALC-NaOH Na-Citrate method (as is used on respiratory specimens) for liquid MGIT 
culture. If contaminated, the isolate will be re-decontaminated once and then discarded thereafter. 
Stool is currently not endorsed as a specimen type for the Xpert MTB/RIF assay and is thus not 
considered in the routine setting.   
An alternative molecular detection method, the HAIN FluoroType assay, has been successfully used in 
adults using respiratory specimens. The FluoroType MTB test combines the use of specific primers and 
DNA amplification with melting curve analysis. The assay showed a sensitivity of 88.1% and a 
specificity of 98.9% compared to culture results with 0.7% of samples yielding invalid results (84) in a 
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recent study of adult patients. However, there are limited published data on the use of the automated 
FluoroType assay with stool specimens from children and adults (84). 
 
1.5 Problem statement 
 
The diagnosis of TB in children is problematic due to a combination of factors including the 
paucibacillary nature of disease associated with low smear, culture and Xpert sensitivities; the 
challenges in obtaining a representative specimen especially from children who cannot expectorate 
or from inaccessible extrapulmonary sites. A timely diagnosis remains essential due to rapid disease 
progression in children. As a result, treatment of children with possible TB is often started empirically 
before bacteriological confirmation is obtained. There is an urgent need to improve diagnostic 
algorithms, including faster and more accurate molecular confirmation methods with the addition of 
at least one first-line drug (preferably RIF) susceptibility profile. Accurate, rapid and cost-effective 
processing and testing methods for the detection of M. tuberculosis and associated drug-resistance 
from non-invasive stool specimens need to be established before stool can be adopted as a routine 




To evaluate the diagnostic utility of stool specimens using different protocols for the molecular 
detection of Mycobacterium tuberculosis in children investigated for suspected intrathoracic TB with 




1) To determine the diagnostic performance of the Xpert MTB/RIF assay using:  
(a) decontaminated stool specimens; and  
(b) untreated raw stool specimens. 
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2) To determine the diagnostic performance of the Xpert MTB/RIF assay using a modified Xpert 
Tube Fill protocol on extracted DNA (FastDNA® Spin for Soil Kit (MP biomedicals)) from:  
(a) decontaminated stool specimens; and  
(b) untreated raw stool specimens. 
3) To determine whether lyophilisation of stool specimens in combination with manual DNA 
extraction (QIAamp® DNA Stool Mini Kit (Qiagen)) enhances the diagnostic utility of the Xpert 
MTB/RIF assay using: 
(a) a modified Xpert Tube Fill protocol  
(b) the FluoroType (Hain Lifescience GmbH, Nehren, Germany) system 
4) To determine whether lyophilisation of stool specimens in combination with an automated 
DNA extraction platform (GenoXtract (GXT, Hain Lifescience GmbH, Nehren, Germany)) 
enhances the diagnostic utility of the Xpert MTB/RIF assay using: 
(a) a modified Xpert Tube Fill protocol 




Stellenbosch University  https://scholar.sun.ac.za
 23 
 
CHAPTER TWO: Materials and methods 
 
2.1 Study Setting and Laboratory Safety  
 
This is a laboratory-based sub-study nested within a large prospective diagnostic cohort study entitled 
“Diagnostic yield and treatment response in childhood intra-thoracic tuberculosis: effect of disease 
severity” (Study PI: E. Walters). The prospective, hospital-based study was conducted in the South 
African National Accreditation System (SANAS) accredited (Appendix I) Biosafety Level 2 (BSL2) 
microbiology laboratory of the National Health Laboratory Service (NHLS) located at Tygerberg 
Hospital and the Division of Medical Physiology and Division of Molecular Biology and Human 
Genetics, Faculty of Medicine and Health Sciences of the University of Stellenbosch, Tygerberg 
Campus. All positive cultures identified with genotypic resistance to rifampicin were sent to the SANAS 
accredited NHLS TB laboratory in Green Point (GP), Cape Town for second-line phenotypic susceptibly 
testing (ofloxacin and amikacin) using the MGIT indirect proportion method.  
 
2.2 Study Population 
 
The patient population included children younger than 13 years of age with and without HIV co-
infection who were routinely evaluated for suspected intrathoracic (pulmonary) TB at the Tygerberg 
Children’s and Karl Bremer Hospitals. Written consent for participation in the study was obtained from 
parents/legal guardians; in addition, assent was obtained from children ≥7 years of age, who 
demonstrated adequate understanding. Ethical approval for the study was given by the Health 
Research Ethics Committee, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape 
Town, South Africa (Ethics reference number N11/09/282) (Appendix A). 
 
2.3 Inclusion Criteria 
 
Eligibility criteria for the clinical study included: Children less than 13 years of age, weighing more than 
2.5 kg (as the study includes neonates) who were identified in hospital (inpatient or outpatient) with 
suspected intrathoracic TB (including suspected MDR-TB) based on persistent unremitting cough (or 
cough significantly worse than usual in a child with chronic lung disease including HIV-related) of >2 
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weeks duration and unresponsive to a course of appropriate antibiotics, poor growth documented 
over the preceding 3 months, persistent unexplained lethargy or reduced playfulness/activity 
reported by the caregiver, or unexplained fever >7 days. In addition, children <2 years of age were 
also eligible if they reported any duration of cough together with ≥1 of: a) documented exposure to a 
known TB source case (regardless of smear status), b) recent Mantoux TST conversion or reactive TST 
if not previously done or c) CXR suggestive of TB. In infants 0-60 days, additional inclusion criteria were 
unresponsive neonatal pneumonia or unexplained hepatosplenomegaly or sepsis-like illness. 
 
2.4 Exclusion criteria  
 
For the clinical study, children who had received >1 day of antituberculosis treatment before the first 
respiratory sample was collected, who had unstable clinical status as a contra-indication to intensive 
respiratory samples collection, who resided in a remote location, were excluded from the study. In 
addition, for this laboratory sub-study, participants who did not produce at least one stool specimen 
at enrolment were excluded. 
 
2.5 Clinical investigation and specimen collection 
 
Clinical investigations included a detailed history and examination, Mantoux TST, CXR, HIV test (HIV 
DNA PCR in children <18 months old, HIV ELISA in older children) and intensive specimen collection.  
 
2.6 Respiratory specimen collection and transportation 
 
Up to 6 respiratory specimens were collected over 2 days by trained nursing staff at participant 
enrolment inside a dedicated cough room in the hospital ward following infection control standards 
(Appendix L). GA and ES specimens were collected in 50 ml conical centrifuge tubes (LASEC SA) after 
a minimum 4 hour fasting period whilst IS and NPA specimens were collected in standard mucus 
extractor containers (25 ml, LASEC SA) after a minimum fast of 2 hours. Specimen pH was measured 
using disposable non-bleeding paper pH indicator sticks (Fisherbrand, Fisher Scientific, Suwanee, Ga, 
USA) and recorded in single pH units (pH 0-pH 14) using the supplied colour comparison chart. Acidic 
GA specimens were neutralised at the time of collection to pH 6-pH 7 by titrating small volumes of 4% 
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sodium bicarbonate solution (Appendix B). All specimens were placed in individual sealable transport 
bags. Specimen containers were labelled with unique barcoded identifiers and were accompanied by 
specimen specific documentation which was placed in a separate outer pocket of the transport bag. 
All containers and transport bags were disinfected (alcohol, 70%) before transportation in a transport 
box containing ice bricks (2-8°C) to the microbiology laboratory of the NHLS at Tygerberg Hospital. 
Specimens were refrigerated (2-8°C) until processing within 3 days of collection. Transport 
temperatures were recorded on study specific forms (Appendix J) and fridge temperatures were 
monitored by an electronic monitoring system. 
 
2.7 Respiratory specimen processing 
 
Appropriate personal protective equipment and clothing were used at all times when handling and 
processing specimens. Workbench and cabinet surfaces were cleaned and sterilized before and after 
specimen handling and all biohazardous waste was properly disposed of (85). Reagents were freshly 
prepared, replaced regularly and only one specimen container was open at any given time to limit 
cross contamination. 
 
2.7.1 Digestion and decontamination 
 
The labelled specimens were received and all patient plus specimen identification labels were 
captured onto the NHLS Laboratory Information System (LIS; DISA/Trakcare). Specimens were 
removed from the transport bag inside the biosafety cabinet and any leaked specimens were properly 
discarded and all relevant specimen information was recorded. Specimens were transferred to a 
sterile 50 ml conical centrifuge tube (except for specimens already received in a conical tube). For 
specimens, less than 3 ml in volume, 0.67 M PBS (pH 6.8; NHLS GP, South Africa) was added to a total 
volume of 3 ml (visually estimated using a pre-labelled 50 ml conical centrifuge tube for volumes less 
than the calibrated 5 ml). To each specimen, an equal volume of NALC-NaOH-sodium citrate (100 ml 
solution: 5.0% NaOH solution mixed 1:1 with 2.9% sodium citrate solution, and 0.5 g NALC) was added 
prior to vortex mixing and incubation for 17 minutes at room temperature (41). Specimens were 
neutralised by the addition of PBS up to the 40 ml mark on the conical container followed by 
centrifugation at 3000xg at 4°C for 20 minutes. The supernatants were decanted into a liquid waste 
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bottle and the sediments resuspended in approximately 3 ml PBS (decontaminated specimen 
suspension) (40). 
 
2.7.2 Concentrated smear microscopy 
 
One drop of decontaminated specimen suspension was mixed with a drop of TB precipitating fluid 
(NHLS, GP) on a labelled microscope slide creating a smear size of between 1.5 and 2.0 cm2. The 
smears were dried on a heating block at 70°C for 2 hours before staining with Auramine O solution 
(NHLS). Auramine smears were fixed with methanol for 30 seconds, flooded with Auramine O stain 
and incubated at room temperature for 20 minutes. Excess Auramine O stain was rinsed off with tap 
water and the smear was decolourised with 0.5% Acid Alcohol for approximately 2 minutes followed 
by rinsing. The smears were flooded with potassium permanganate counter stain for 2 minutes 
followed by rinsing and air-drying. Acid fast organisms emitted a bright yellow fluorescence when 
viewed under a fluorescent microscope. At least 100 fields were viewed (at 40x magnification) per 
smear and results were reported as negative, scanty, 1+, 2+ or 3+ according to the WHO/IUATLD 
standardised guidelines (40). Ten percent of all negative and all positive smears (including positive 
(H37Rv laboratory strain) and negative control slides) were checked by a second reader daily. 
 
2.7.3 Liquid culture 
 
From the decontaminated specimen suspension, 0.5 ml was inoculated into a 7 ml MGIT containing 
0.8 ml BBL MGIT PANTA/OADC mixture (Becton Dickson; Appendix B) followed by incubation in the 
Bactec MGIT 960 system at 37°C. Bacterial growth was monitored hourly on the Bactec MGIT 960 
automated liquid culture system. Once the MGIT tubes were in the Bactec system, they were 
incubated for a maximum of 42 days. If no significant change in fluorescence was automatically 
detected by the system within 42 days, the culture was reported as being negative for MTB. Negative 
cultures were manually checked for any visible growth after the incubation period before being 
discarded. If any visible growth was observed the specimen would be processed further as a positive 
culture for further identification. Cultures reported as positive by the Bactec system, or where visible 
growth was observed, were batched and processed weekly for further identification and DST. The 
Bactec system also records the TTD for each positive culture. Daily negative (PBS), and weekly positive 
(H37Rv laboratory reference strain) controls were included. All reagents are checked before use to 
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enforce expiration dates and batch verification tests (H37Rv serial dilutions) for MGIT tubes are done 
on receipt. 
 
2.7.4 Xpert MTB/RIF Assay 
 
Specimen testing on the Xpert MTB/RIF Assay was done as per manufacture’s instruction. Briefly, 1 ml 
of the decontaminated specimen suspension was mixed with 2 ml Xpert MTB/RIF sample reagent (1:2 
ratio) in a sterile 50 ml conical tube. This mixture was incubated at for 10 minutes at room 
temperature, briefly mixed by inverting the tube 10 times and incubated for a further 5 minutes. The 
mixture was completely transferred to a pre-labelled Xpert MTB/RIF cartridge and analysed in the 
GeneXpert® instrument (GeneXpert Dx software version 4.4a). If an “invalid”, “error” or “No Result” 
result (Table 2.1) occurred; and if sufficient decontaminated specimen suspension remained (1 ml), 
the Xpert MTB/RIF assay was repeated once. 
 






NO RESULT N/A N/A 
ERROR N/A N/A 
INVALID N/A N/A 










2.7.5 Ziehl-Neelsen (ZN) microscopy 
 
For all positive MGIT cultures, one drop of the resuspended culture was added to a drop of TB 
precipitating fluid (NHLS) on a labelled microscope slide and dried on a hot plate for at least 2 hours 
at 70°C. All staining steps were performed inside a fume hood (NHLS). Microscope slides for ZN 
staining were flooded with carbol fuchsin stain (NHLS) and gently heated for approximately 1 minute 
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with an open flame until steam arose, melting the outer wax layer of any AFB. The smears were 
incubated at room temperature for 5 minutes and excess carbol fuchsin stain was rinsed off with tap 
water. The smears were decolourised with acid alcohol (3%; NHLS) for approximately 2 minutes 
followed by rinsing, with tap water. Slides were then flooded with methylene blue (0.3%; NHLS) 
counter stain for approximately 2 minutes followed by rinsing and air-drying. Acid-fast organisms 
appeared as reddish rod-shaped structures often forming cord-like structures when viewed under a 
light microscope. 
 
2.7.6 Blood Agar Plates (BAP) 
 
All positive MGIT cultures were plated out on BAP and incubated at 35°C for at least 24 hours to detect 
any contamination. BAP results were recorded as “growth” or “no growth”. The combination of ZN 
microscopy and BAP was used as a purity check to confirm the presence of AFB and to rule out 
contaminated cultures. Positive MGIT cultures that displayed acid-fastness after ZN staining along 
with no contaminant growth on the BAP had further identification and DST done (Appendix G). 
Contaminated cultures that displayed acid-fastness were re-decontaminated once more to obtain a 
pure culture for DST. Repeat decontamination was done by adding the contents of the MGIT tube to 
a sterile 50 ml conical tube with the addition of an equal volume of 4% NaOH, followed by incubation 
for 17 minutes at room temperature. The specimen was then processed further as per Section 2.7.1 
and re-incubated (up to 42 days). Continued contaminated cultures not displaying acid-fastness were 
recorded as “contaminated” and no further testing was done.  
 
2.7.7 HAIN GenoType®MTBDRplus Assay 
 
Genomic DNA was extracted from positive MGIT cultures using the GenoLyse method (86) as per the 
manufacturer’s instructions (HAIN GenoLyse VER 1.0, Hain Lifescience GmbH, Nehren, Germany). 
Briefly, 1 ml of the positive MGIT liquid media was transferred to a pre-labelled sterile 1.5 ml plastic 
screw cap tube and centrifuged for 15 minutes at 10 000xg. Negative (sterile water) and positive 
(H37Rv laboratory reference strain) controls were included in each batch. The supernatants were 
discarded and sediments resuspended in 100 µl lysis buffer (A-LYS) by vortex mixing. Aliquots were 
heat inactivated at 95°C for 5 minutes and sonicated for 15 minutes followed by the addition of 100 
µl neutralisation buffer (A-NB) and vortex mixing for 5 seconds. The specimens were centrifuged for 5 
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minutes at 10 000xg and 5 µl of the supernatant was transferred to a PCR tube for DNA amplification 
and the remainder was transferred to a sterile 1.5 ml plastic screw cap tube for short term storage at 
2-8°C if repeat testing was required.  
The GenoType®MTBDRplus test was performed for genotypic identification of MTBC and drug 
sensitivities to RIF and INH as per the manufacturer’s instruction (MTBDRplus VER 2.0, Hain Lifescience 
GmbH, Nehren, Germany). Resistance to RIF was identified by detection of the most significant rpoB 
gene mutations. High level INH resistance was identified by the detection of mutations in the katG 
gene, whilst low level INH resistance was identified by mutations in the inhA promoter region.  
The DNA amplification mix (AM) was prepared as follows: Stored amplification reagents, AM-A and 
AM-B (-20°C) were thawed to room temperature, and 10 µl AM-A and 35 µl AM-B were added to each 
5 µl of extracted DNA specimen (final reaction mix volume of a 50 µl). To limit the risk of cross 
contamination the DNA extraction, PCR mix preparation, DNA addition and hybridisation steps were 
conducted in separate rooms. The PCR amplification conditions were as follows: initial denaturation 
at 95°C for 15 minutes, 10 cycles of denaturation at 95°C for 30 seconds, 65°C for 2 minutes, 20 cycles 
of denaturation at 95°C for 25 seconds with annealing at 50°C for 40 seconds, elongation at 70°C for 
40 seconds and final extension at 70°C for 8 minutes (standard ramp rates). Following PCR 
amplification, the chemically denatured amplicons (single stranded) were hybridised (reverse 
hybridisation) to the membrane strips (coated with specific probes complimentary to the amplified 
nucleic acids) in the TwinCubator according to the manufacturer’s instructions. Briefly, 20 µl of biotin 
labelled amplicon was hybridised onto the strip with 1 ml hybridisation buffer. After stringent buffer 
washing, the streptavidin-alkaline-phosphatase conjugate was added to the strip. An alkaline 
phosphatase mediated staining reaction occurred where the probe and amplicon hybridised, resulting 
in the appearance of a dark banded pattern. Hybridisation patterns were interpreted according to the 
manufacturer’s guidelines (HAIN MTBDRplus VER 2.0). Results were reported as MTB negative or MTB 
positive with respective resistance profiles when applicable (Table 2.2). Cultures suspected of being 
NTM (ZN positive without characteristic cording pattern and negative by the MPT64 assay) were 
tested with the GenoType Mycobacterium CM/AS kit as per manufacturer’s instruction (Hain 
Lifescience GmbH, Nehren, Germany). RIF resistant cultures were submitted to the NHLS GP 
laboratory for 2nd line susceptibility testing by the agar indirect proportion method (critical 
concentrations: ofloxacin (2.0 µg/ml and amikacin 4.0 µg/ml). 
  
Stellenbosch University  https://scholar.sun.ac.za
 30 
 
Table 2.2. Summary of resistance profiles and further testing 
MTBC 
(MTBDRplus) RIF INH 
Second-line 
DST 




Not detected N/A N/A N/A YES 
Detected Susceptible Susceptible NO NO 
Detected Resistant Susceptible YES NO 
Detected Susceptible Resistant YES NO 
Detected Resistant Resistant YES NO 
 
2.8 Stool Specimen collection and transportation 
 
During the initial phase of this study, stool specimens obtained between April 2013 and June 2014 
were collected by trained nursing staff in sterile containers (25 ml Fecal Cup With Spoon, LASEC SA) 
with an equal volume of sterile saline added to each specimen by the nursing staff at the time of 
collection. Specimens were homogenised by inverting the tube 10-15 times by hand and transported 
to the lab to be stored at (2-8°C) until further analysis by MGIT culture, concentrated smear 
microscopy and Xpert MTB/RIF assay testing (Method A) as summarised in Table 2.3.  
 
Table 2.3. Stool study protocol: Method A 
Stool Quantity Use 
1 portion only 0.3 g to 5.0 g 
Concentrated smear microscopy, MGIT 
culture and Xpert MTB/RIF analysis (Method 
A) 
Decontaminated remainder stored in PBS at  
-20°C 
 
Stool specimens processed using this method (Method A) were also tested by MGIT culture. However, 
due to a high proportion of contaminated stool cultures (41.5%; Walters E, unpublished data), stool 
culture was discontinued in June 2014. After June 2014, raw stool specimens were collected for direct 
Xpert MTB/RIF investigation, without the addition of sterile saline (Method B, Table 2.4). Stool 
specimens were collected from each participant at the baseline visit and these were split into two 
stool portions (portion 1 and portion 2) in separate containers (25 ml Fecal Cup With Spoon, LASEC 
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SA) by trained nursing staff. The first portion was analysed by direct Xpert MTB/RIF assay (Method B) 
and the second portion was stored at -20°C until lyophilisation.  
 
Table 2.4. Stool study protocol: Method B 
Stool Quantity Use 
Portion 1 0.3 g to 5.0 g Direct Xpert MTB/RIF analysis (Method B) 
Portion 2 0.3 g to 5.0 g Raw stool stored at -20°C 
 
2.9 Stool specimen processing 
 
Stool specimens were processed according to the study specific protocols (Method A and Method B) 
and the remainder from Method A and portion 2 from Method B were stored at -20°C for further 
analysis.  
 
2.9.1 Method A - Stool specimen decontamination, concentration and MTB detection 
using smear, culture and the Xpert MTB/RIF assay 
 
Stool specimens in saline buffer were received in the lab and 5-10 ml PBS buffer was added to each 
container. The specimens were homogenised by vortex mixing for 20 seconds followed by incubation 
at room temperature for 5 minutes allowing the settling of large debris particulates. Five millilitres of 
this homogenised stool supernatant was transferred to a labelled 50 ml conical centrifuge tube. An 
equal volume of NALC-NaOH-sodium citrate was added followed by vortex mixing and incubation for 
17 minutes at room temperature. Specimens were neutralised by the addition of PBS up to the 40 ml 
mark on the conical container followed by centrifugation at 3000xg at 4°C for 20 minutes. The 
supernatants were decanted into a liquid waste bottle and the sediments resuspended in 
approximately 3 ml PBS (decontamination protocol, section 2.7.1). The decontaminated  resuspended 
stool sediments were analysed by concentrated smear microscopy (Auramine), liquid (MGIT) culture 
and Xpert MTB/RIF Assay as previously described for respiratory specimens in section 2.7 (one drop 
for smear microscopy, 0.5 ml for liquid culture and 1 ml for Xpert) and the remainder of this 
resuspended sediment was stored at -20°C (Figure 2.1). 




2.9.2 Method B - Stool specimen concentration and MTB detection using direct Xpert 
MTB/RIF detection  
 
A large scoop (0.3 g-5.0 g) of portion 1 stool specimen was added to a 50 ml conical centrifuge tube. 
The stool specimens were homogenised in 10 ml PBS buffer by vortex mixing for approximately 20 
seconds (or until completely homogenised) followed by centrifugation at 3000xg for 20 minutes at 
4°C. The supernatants were discarded and the sediments resuspended in up to 10 ml PBS buffer by 
vortex mixing for approximately 20 seconds. The resuspended sediments were centrifuged briefly (1 
second at 2000xg) to settle large debris particulates. One millilitre of the supernatant was aspirated 
from the bottom layer (above sediment) and used for direct Xpert MTB/RIF analysis as per section 
2.7.7 (Figure 2.1). If an indeterminate result occurred, the Xpert MTB/RIF assay was repeated once 
per stool specimen using the remaining supernatant from the brief centrifugation step. 
 
 
Figure 2.1. Overview of stool processing Methods A and B 
  





The decontaminated stool suspension (remainder from Method A) was not lyophilised but subjected 
to Method 1 (section 2.10.1), whereas portion 2 (raw) stool, stored from stool specimens collected 
and tested by Method B, was either thawed and used for Method 2 or subjected to the lyophilisation 
process and subsequently tested using Methods 3-6 (section 2.10.3 - 2.10.6 ). Stored raw stool 
specimens (-20°C) were thawed at room temperature and transferred to a sterile 50 ml conical 
centrifuge tube. The mass of each specimen, pre-lyophilisation and post-lyophilisation, was recorded. 
One hundred microliters of sterile 10x Tris-HCL (10 mM)/EDTA (10 mM) pH 8 (TE) buffer (Appendix B) 
was added to each specimen to preserve the DNA. The specimens were heat inactivated at 80°C for 1 
hour in a water bath (Memmert, LASEC SA). Heat inactivated stool specimens were lyophilised prior 
to DNA extraction to allow standardisation of input specimen mass. 
The prepared heat inactivated specimens were sealed with a layer of parafilm to prevent cross-
contamination during lyophilisation. Specimens were placed in a metal tray; small openings in the 
parafilm were made using a 1 ml sterile tuberculin syringe (LASEC SA) to allow for moisture escape 
and the specimen tray was submerged in liquid nitrogen for approximately 30 seconds (flash freezing). 
The frozen specimens were placed in the vacuum chamber of the Labconco freeze dryer (Vacutec, 
South Africa). The sealed chamber was left to reach a vacuum at 37 Pascals at -49°C and specimens 
were freeze-dried for 24 hours. Specimens that were not completely dry (visually assessed) were 
lyophilised for an additional 24 hours. 
 
2.9.4 Manual DNA extraction protocols 
 
2.9.4.1 FastDNA® Spin for Soil Kit (MP biomedicals) 
 
The stored decontaminated stool suspension (remainder from method A, Section 2.9.1) or the stored 
raw stool (Portion 2, remainder from Method B) was thawed at room temperature and 100 µl was 
transferred to a lysing matrix E tube (used in Method 1 and Method 2 respectively). Genomic DNA was 
extracted using the FastDNA® Spin for Soil Kit as per the manufacturer’s instructions (Appendix C) 
from these stool specimens. The DNA was eluted in 200 µl elution buffer instead of the recommended 
100 µl to accommodate the recommended starting volume of the Xpert Tube Fill protocol (Section 
2.9.6.1).  




2.9.4.2 QIAamp® DNA Stool Mini Kit  
 
The QIAamp DNA Stool Mini Kit extraction protocol was performed from lyophilised specimens 
(Sections 2.10.3, 2.10.4; and 2.9.3). Genomic DNA was extracted from the lyophilised stool specimens 
according to the manufacturer’s instructions (Appendix D) with some protocol modifications, namely: 
The starting amount for each lyophilised stool specimen was kept constant at 100 mg (+- 5 mg) instead 
of the recommended 180-220 mg of raw stool for consistency. The lysis temperature was increased 
from 70°C to 95°C for difficult to lyse cells (Gram-positive bacteria). Purified genomic DNA was eluted 
in 200 µl elution buffer to accommodate the Xpert Tube Fill protocol (Section 2.9.6.1.). 
 
2.9.5 Automated Hain GenoXtract DNA extraction protocol 
 
Automated DNA extraction was done from lyophilised stool specimens using the GenoXtract along 
with the GenoXtract DNA/RNA Extraction Kit as per the manufacturer’s instructions (Appendix E). 
Briefly, lyophilised specimens were swabbed (approx. 100 mg) and reconstituted in 100 ml of stool 
stabiliser. Pump-pipette-tip units, reagent cartridges and elution containers were mounted in the 
GenoXtract equipment. The GenoXtract software was set to elute the isolated DNA into 200 µl elution 
buffer following the 40-minute protocol. 
 
2.9.6 Molecular detection of MTB 
 
2.9.6.1 Xpert Tube Fill protocol 
 
Extracted genomic DNA was tested on the Xpert MTB/RIF using a Tube Fill protocol and software 
adaptation. In brief, the cartridge lid was opened and 200 µl of purified DNA was transferred to the 
6th well of an Xpert MTB/RIF cartridge (Figure 2.2) using a sterile 1 ml syringe (Avacare, LASEC SA) and 
a spinal needle (21GX1’’ 0.8x25 mm TW, Avacare, LASEC SA). The DNA mixture was added close to the 
bottom of the well (approximately 1 mm from the bottom) ensuring that no air bubbles were present 
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and without piercing the container. This method bypasses the initial chambers responsible for 
specimen washing and DNA extraction.  
 
 
Figure 2.2. Schematic representation of Xpert Tube Fill protocol 
 
The cartridges were analysed using the GeneXpert instrument with a preloaded Tube Fill (ADF file) 
software add-on. Once the cartridge information was manually entered, by following the software 
prompts, the specific MTB Tube Fill (version 1.0) assay was selected from the dropdown list. The 
cartridges were placed in the module and the automated system generated results within 1 hour 35 
minutes.    
 
2.9.6.2 Fluorotype MTB protocol (Hain Lifescience GmbH, Nehren, Germany) 
 
The Fluorotype MTB test was done on the FluoroCycler 12 instrument as per the manufacturer’s 
instructions (Appendix F). Briefly, PCR reaction mixtures were freshly prepared by combining 3 µl 
amplification mix A (AM-A) with 7 µl of amplification mix B (AM-B) in 200 µl PCR reaction tubes 
(Sarstedt, Nürnberg Germany). Six microliters of the GenoXtract extracted DNA solution was added to 
10 µl of amplification mix. Kit controls included 6 µl of sterile PCR-grade water (non-template control) 
and 6 µl of C + FT MTB (positive control). The PCR mixtures were loaded onto the FluoroCycler 
instrument with the accompanying automated analysis FluoroSoftware IVD 1.1.0. The melting curve 
for the amplification control was expected at 70.5°C (+/- 3°C) and a positive MTBC result was expected 
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at 60.0°C (+/- 3°C). Analysis software expressed results as either: “no MTB complex DNA detected”; 
“MTB complex DNA detected”; “Not interpretable”; or “Invalid” (Table 2.5). 
 
Table 2.5. FluoroType result interpretation 
Software Interpretation Explanation 
MTB complex DNA 
detected There is a peak at the MTB complex-specific melting point 
No MTB complex DNA 
detected There is no peak at the MTB complex-specific melting point 
Negative control valid As expected, no peak at the MTB complex-specific melting point 
Positive control valid As expected, there is a peak at the MTB complex-specific melting point 
Not interpretable 
Peaks detected outside of the control or MTBC-specific melting 
point 
Additional peaks detected 
Invalid 
No valid peaks detected 
Discordant control results 
 
2.10 Stool specimen molecular detection protocols  
 
In an attempt to improve the sensitivity of Xpert on stool specimens for the bacteriological 
confirmation of TB in children, combinations of DNA extraction methods and molecular detection 
platforms (Methods 1 – 6, Figure 2.3) were used. 
 




Figure 2.3. Overview of stool processing methods 1 - 6 
 
2.10.1 Method 1 – FastDNA DNA extraction followed by the Xpert Tube Fill protocol on 
decontaminated stool specimens 
 
Genomic DNA was extracted from the stored remainder of the decontaminated stool suspension of 
method A (Section 2.9.1) using the FastDNA® Spin for Soil Kit as per section 2.9.4.1. Molecular 
detection was completed using the Xpert Tube Fill platform (Section 2.9.6.1). 
 
2.10.2 Method 2 – FastDNA DNA extraction followed by the Xpert Tube Fill protocol on 
untreated raw stool specimens 
 
When Method A was discontinued, stool specimens were no longer stored in the post-
decontamination fluid (remaining NALC-NaOH-sodium citrate-PBS buffer) and subsequently DNA 
extraction was completed on raw stool specimens (portion 2 specimens, Method B) using the 
FastDNA® Spin for Soil Kit as described above (Section 2.10.1). Molecular detection was completed 
using the Xpert Tube Fill protocol (Section 2.9.6.1). 
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2.10.3 Method 3 – QIAamp DNA extraction followed by the Xpert Tube Fill protocol on 
lyophilised stool specimens 
 
A major challenge for the molecular processing of stool specimens was the variability in stool 
consistencies. A reproducible starting mass could not be consistently obtained for the DNA protocols. 
It was decided that the removal of water from the stool specimens by lyophilisation would allow for 
an easy-to-work-with specimen and potentially concentrate any intact or extracellular MTB present in 
the specimen. 
Stored raw stool specimens were lyophilised (Section 2.9.3) prior to manual DNA extraction using the 
QIAamp® DNA Stool Mini Kit (Section 2.9.4.2). Due to availability and cost limitations, the FastDNA® 
Spin for Soil Kit was replaced with the QIAamp® DNA Stool Mini Kit (serial dilutions using H37Rv yielded 
similar results for both kits). 
 
2.10.4 Method 4 – QIAamp DNA extraction followed by the FluoroType protocol on 
lyophilised stool specimens 
 
The HAIN FluoroType protocol was considered as a detection assay as it has the ability to test multiple 
specimens simultaneously. DNA was extracted from lyophilised stool using the QIAamp® DNA Stool 
Mini Kit (Section 2.9.4.2) and molecular detection was done using the HAIN FluoroType protocol 
(Section 2.9.6.2).  
 
2.10.5 Method 5 – GenoXtract DNA extraction followed by the FluoroType protocol on 
lyophilised stool specimens 
 
The automated protocol of extracting numerous specimens simultaneously seemed more feasible 
than the hands-on and more labour-intensive manual DNA extraction protocols. DNA was extracted 
from lyophilised stool using the automated HAIN GenoXtract (Section 2.9.5) and molecular detection 
was done on the using the HAIN FluoroType platform (Section 2.9.6.2).  
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2.10.6 Method 6 – GenoXtract DNA extraction followed by the Xpert Tube Fill protocol on 
lyophilised stool specimens 
 
To compare the two detection platforms, DNA extracted using the automated HAIN GenoXtract was 
tested on the Xpert Tube Fill detection platform. 
Table 2.6. Summary of stool processing methods 
Method Description Stool processing Extraction Amplification Detection 
A Decontaminated Standard A 
Raw + 
Decontaminated (Xpert)* (Xpert)*  Xpert 







+ PBS (Stored  
-20°C) 
Soil kit (Tube Fill)** Tube Fill 
2 Manual Extraction/ Tube Fill 
Raw (Stored  
-20°C) Soil kit (Tube Fill)** Tube Fill 
3 Manual Extraction/ Tube Fill Lyophilised Qiagen kit (Tube Fill)** Tube Fill 
4 Manual Extraction/ FluoroType Lyophilised Qiagen kit FluoroType FluoroType 
5 Automated Extraction/ FluoroType Lyophilised GenoXtract FluoroType FluoroType 
6 Automated Extraction/ Tube Fill Lyophilised GenoXtract (Tube Fill)** Tube Fill 
* DNA extraction and amplification occurs within the Xpert cartridge  
** DNA amplification occurs within the Xpert cartridge 
 
2.10.7 Proof-of-concept protocol 
 
A dilution range (undiluted to 10-7) was made of purified H37Rv DNA (laboratory reference strain, 25 
ng/µl) to determine the detection limit of the Xpert Tube Fill and FluoroCycler protocols and to serve 
as a proof-of-concept for the recovery of MTB DNA from spiked stool specimens. This was done for 
Methods 1,2,3,5 and 6. Method 4 did not have spiking experiments done. The number of molecules 
(N) per mole present in the H37Rv DNA dilution range was calculated according to the following 
equation: 
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𝑵𝑵 = 𝒏𝒏𝑵𝑵𝒏𝒏 
                  = � 𝑪𝑪
𝑴𝑴𝑴𝑴 �𝑵𝑵𝒏𝒏 
 
𝑵𝑵𝒏𝒏 = the Avogadro constant = 6.023 x1023  
𝑪𝑪= initial DNA concentration 
𝒏𝒏= number of mole = 𝑪𝑪/𝑴𝑴𝑴𝑴 
𝑴𝑴𝑴𝑴= number of base pairs in MTB genome (4.4 x106) x average molecular weight of a base 
pair (700) 
 
The GeneXpert targets the rpoB gene which is present in single copy in the MTB genome, therefore 
the dilution range represented 0 to ~5 million bacteria per µl (Table 2.7). 
 
Table 2.7. Number of molecules in each pure H37Rv DNA dilution 
Sample Dilution Sample Concentration (ng/µl) Number of molecules/μl 
(100) 25 4888799 
(10-1) 2.5 488880 
(10-2) 0.25 48888 
(10-3) 0.025 4889 
(10-4) 0.0025 489 
(10-5) 0.00025 49 
(10-6) 0.000025 5 
(10-7) 0.0000025 ≤1 
 
2.11 Analysis plan and definitions 
 
The primary reference standard for diagnostic accuracy calculations was a composite reference 
standard defined as respiratory mycobacteriology. This composite reference standard included any 
MGIT culture and/or Xpert MTB/RIF results from any respiratory specimens collected for the study. 
The reference was considered positive if any of these results were positive, and negative if all of the 
results were negative. Although false positive results on the reference standard are always a 
possibility, the study population consisted of children with a high pre-test probability of having active 
TB disease. Given the high positive likelihood ratios for both MGIT culture and Xpert MTB/RIF, the 
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post-test probability of active TB for children with positive test results is very high. Furthermore, 
recently developed consensus case definitions for PTB in children classify as a case of confirmed TB 
any child presenting with symptoms, and with MTB identified by mycobacterial culture or Xpert 
MTB/RIF on any respiratory specimens (87).  
Due to possible bias resulting from the absolute number of respiratory specimens processed (up to 6) 
compared to only one stool specimen tested on Xpert MTB/RIF, Xpert Tube Fill and/or the HAIN 
FluoroType assay, a secondary reference standard was defined as the “first respiratory specimen” 
collected from any participant for the study, as one sample better reflects the routine practice in our 
setting and is a fairer comparison. All ZN negative and contaminated (after repeat decontamination) 
and NTM culture results were excluded from analyses and “Indeterminate” results were defined as 
“error”, “invalid” or “no result” for Xpert MTB/RIF, “error” only for Tube Fill assays, and as “not 
interpretable” or “invalid” for the FluoroType assay. Indeterminate rate was defined as the number of 
indeterminate results over the number of stool specimens tested for the composite reference 
standard, and was calculated separately for each individual method. All indeterminate results and any 
expected tests that were not done for any reason were omitted from sensitivity and specificity 
calculations.  
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CHAPTER THREE: Results 
3.1 Stool processing from study specific protocols (Method A and B) 
 
A total of 517 children were enrolled of whom 405 provided a stool sample for analysis, 109 
participants did not provide a stool specimen and 3 participants withdrew from the study before any 
specimens were collected (Figure 3.1).  
 
 
Figure 3.1. Overview of Stool results processed by Method A and B 
 
3.1.1 Method A - Stool specimen decontamination, concentration and MTB detection 
using Xpert MTB/RIF assay 
 
A total of 195 participant stool specimens were processed by Method A. The sensitivity and specificity 
(Excel developed calculation based on Chi-squared analysis) of stool Xpert compared to the composite 
reference standard were 26.7% and 97.9% (n = 195), while the performance improved to 47.1% and 
97.8%, respectively, compared to the first respiratory specimen culture (n = 166) and to 75.0% and 
96.3% compared to the first respiratory Xpert (n = 96) (Table 3.1). During the initial phases of the study 
many Xpert MTB/RIF assays were not done on the first respiratory specimen as they formed part of a 
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study-specific protocol where different specimen types were combined for Xpert MTB/RIF detection. 
These specimens were excluded from this analysis. The positive predictive value (PPV) was the highest 
for the composite reference standard and the first respiratory culture at 72.7% and the probability 
decreased for the first respiratory Xpert to 66.7%. The negative predictive value (NPV) was the lowest 
for the composite reference standard at 86.6% and increased to 93.6% and 97.5% for the first 
respiratory culture and Xpert respectively. The overall indeterminate rate was 20/195 (10.3%).   
 
Table 3.1. Method A Results summary 







First Respiratory  
Xpert 
Result POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE 
POSITIVE 8 3 8 3 6 3 
NEGATIVE 22 142 9 132 2 77 
INDETERMINATE 4 16 1 13 1 5 
TOTAL 34 161 18 148 9 85 
Sensitivity 26.7 47.1 75.0 
Specificity 97.9 97.8 96.3 
 
3.1.2 Method B - Stool specimen concentration and MTB detection using direct Xpert 
MTB/RIF detection  
 
208 participant stool specimens were processed by Method B for Xpert MTB/RIF analysis. The 
sensitivity and specificity of stool Xpert compared to the composite reference standard were 40.0% 
and 100% (n = 208), 66.7% and 97.7% compared to the first respiratory specimen culture (n = 198) and 
45.8% and 98.2% compared the first respiratory Xpert (n = 196), respectively. The PPV was the highest 
for the composite reference standard at 100.0% and decreased for the first respiratory culture to 
78.6% and to 71.4% for the first respiratory Xpert. The NPV was the lowest for the composite reference 
standard at 88.8% and increased to 92.6% and 97.2% for the first respiratory culture and Xpert 
respectively. The indeterminate rate was 7/208 (3.4%). 
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Result POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE 
POSITIVE 14 0 11 3 10 4 
NEGATIVE 21 166 13 163 5 173 
INDETERMINATE 2 5 2 4 1 5 
TOTAL 37 171 26 170 16 182 
Sensitivity 40.0 45.8 66.7 
Specificity 100.0 98.2 97.7 
 
3.1.3 Proof-of-concept protocol experiment for DNA extraction protocols 
 
As a proof-of-concept experiment, dilutions of MTB (H37Rv laboratory reference strain) of known 
concentration were used to determine the extraction efficiency of the various DNA extraction and 
molecular detection protocols from DNA inoculated stool specimens. Xpert Tube Fill detection from 
lyophilised stool processed by manual DNA extraction methods (both soil and stool kits) detected MTB 
DNA between 0.25 fg/µl and 2.5 fg/µl, equivalent to 0 – 5 bacteria per µl (Table 3.3). The FluoroType 
assay showed the same extraction efficiency using lyophilised stool with automated GenoXtract. The 
extraction efficiency for MTB DNA extracted from lyophilised stool using the GenoXtract when 
detected on the Xpert Tube Fill assay was however lower at 0.25 pg/µl to 2.5 pg/µl (49 – 490 bacteria 
per µl). MTB DNA was detected at the upper limit or highest DNA concentration of 25 ng/µl (approx. 
5 million bacteria per µl) on all methods, showing that a high concentration of DNA does not interfere 
with the detection assays. 
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(100) 4888799 Detected NOT DONE* Detected Detected Detected 
(10-1) 488880 Detected Detected Detected Detected Detected 
(10-2) 48888 Detected Detected Detected Not Detected** 
Not 
Detected** 
(10-3) 4889 Detected Detected Detected Detected Detected 
(10-4) 489 Detected Detected Detected Detected Detected 
(10-5) 49 Detected Detected Detected Detected Not Detected 
(10-6) 5 Detected Not Detected Detected Detected Not Detected 
(10-7) ≤1 Detected Detected Detected Detected Not Detected 




Detected Not Detected Not Detected 




Detected Not Detected Not Detected 
* Highest and lowest DNA dilution were omitted 
** Possible processing error; not repeated as dilutions on either side detected MTB DNA 
 
3.1.4 Method 1 – FastDNA DNA extraction followed by the Xpert Tube Fill protocol on 
decontaminated stool specimens 
 
DNA was extracted manually from the remainder of the decontaminated stool suspension from 13 
participants (resuspended sediment) leftover from Method A and molecular detection was done using 
the Xpert Tube Fill assay. The sensitivity and specificity of the Xpert assay were 28.6% and 100% 
compared to the composite reference standard, 40.0% and 100% compared to the first respiratory 
culture only and 50.0% and 100% compared to the first respiratory Xpert (Table 3.4). The PPV was 
100.0% for all reference standards whilst the NPV was the lowest for the composite reference 
standard at 54.6% and increased to 72.7% and 81.8% for the first respiratory culture and Xpert 
respectively. No indeterminate results were generated using this method. 
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Table 3.4. Method 1 Results summary 
Method 1: 
Decontaminated 
stool + DNA 
extraction + 
Xpert Tube Fill 
Composite Reference 
Standard 
First Respiratory  
Culture 
First Respiratory  
Xpert 
Result POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE 
POSITIVE 2 0 2 0 2 0 
NEGATIVE 5 6 3 8 2 9 
INDETERMINATE 0 0 0 0 0 0 
TOTAL 7 6 5 8 4 9 
Sensitivity 28.6 40.0 50.0 
Specificity 100 100 100 
 
3.1.5 Method 2 – FastDNA DNA extraction followed by the Xpert Tube Fill protocol on 
untreated raw stool specimens  
 
DNA was extracted manually from 32 raw stool specimens and molecular detection was done using 
the Xpert Tube Fill assay. The sensitivity and specificity of the Xpert assay compared to the composite 
reference standard were 16.7% and 70.8%; and 0.0% and 70.4% compared to both the first respiratory 
culture and Xpert (n = 31) (Table 3.5). The PPV was the highest for the composite reference standard 
at 12.5% and decreased for the first respiratory culture and Xpert to 0.0%. The NPV was the lowest for 
the composite reference standard at 77.3% and increased to 90.5% the first respiratory culture and 
Xpert. The indeterminate rate was 2/32 (6.3%). 





Xpert Tube Fill 
Composite Reference 
Standard 
First Respiratory  
Culture 
First Respiratory  
Xpert 
Result POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE 
POSITIVE 1 7 0 8 0 8 
NEGATIVE 5 17 2 19 2 19 
INDETERMINATE 0 2 0 2 0 2 
TOTAL 6 26 2 29 2 29 
Sensitivity 16.7 0.0 0.0 
Specificity 70.8 70.4 70.4 
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3.1.6 Method 3 – QIAamp DNA extraction followed by the Xpert Tube Fill protocol on 
lyophilised stool specimens  
 
DNA was manually extracted from 63 lyophilised stool specimens and molecular detection was done 
using the Xpert Tube Fill assay. The sensitivity and specificity compared to the composite reference 
standard were 37.0% and 88.9%; 44.4% and 86.7% compared to the first respiratory culture and 66.7% 
and 88.2% compared to the first respiratory Xpert (Table 3.6). The PPV was the highest for the 
composite reference standard at 71.4% and decreased for the first respiratory culture and Xpert to 
57.1%. The NPV was the lowest for the composite reference standard at 65.3% and increased to 79.6% 
and 91.8% for the first respiratory culture and Xpert respectively. No indeterminate results were 
observed (0.0%). 
 
Table 3.6. Method 3 Results summary 
Method 3: 
Lyophilisation + 
Xpert Tube Fill 
Composite Reference 
Standard 
First Respiratory  
Culture 
First Respiratory  
Xpert 
Result POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE 
POSITIVE 10 4 8 6 8 6 
NEGATIVE 17 32 10 39 4 45 
INDETERMINATE 0 0 0 0 0 0 
TOTAL 27 36 18 45 12 51 
Sensitivity 37.0 44.4 66.7 
Specificity 88.9 86.7 88.2 
 
3.1.7 Method 4 – QIAamp DNA extraction followed by the FluoroType protocol on 
lyophilised stool specimens  
 
Only 8 stool samples were tested using this method. DNA was manually extracted from the lyophilised 
stool and molecular detection was done using the HAIN FluoroType platform. Of the 8 specimens 
tested, 6 gave indeterminate results (75.0%). The remaining 2 specimens tested positive on the index 
method as well as all the reference standards. Sensitivity and specificity calculations were not done 
due to the small number of samples included. 
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3.1.8 Method 5 – GenoXtract DNA extraction followed by the FluoroType protocol on 
lyophilised stool specimens 
 
DNA was extracted automatically from the lyophilised stool of 33 participants; and molecular 
detection was done using the HAIN FluoroType platform. The sensitivity and specificity compared to 
the composite reference standard were 75.0% and 85.7%; 75.0% and 63.6% compared to the first 
respiratory culture and 71.4% and 58.3% compared to the first respiratory Xpert (Table 3.7). The PPV 
was the highest for the composite reference standard at 90.0% and decreased for the first respiratory 
culture to 60.0% and to 50.0% for the first respiratory Xpert. The NPV was the lowest for the composite 
reference standard at 66.7% and increased to 77.8% for both the first respiratory culture and Xpert. 
The indeterminate rate was very high at 14/33 (42.4%). 







First Respiratory  
Culture 
First Respiratory  
Xpert 
Result POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE 
POSITIVE 9 1 6 4 5 5 
NEGATIVE 3 6 2 7 2 7 
INDETERMINATE 7 7 6 8 3 11 
TOTAL 19 14 14 19 10 23 
Sensitivity 75.0 75.0 71.4 
Specificity 85.7 63.6 58.3 
 
3.1.9 Method 6 – GenoXtract DNA extraction followed by the Xpert Tube Fill protocol on 
lyophilised stool specimens 
 
DNA was extracted using the automated GenoXtract DNA extraction protocol from the lyophilised 
stool of 49 participants and molecular detection was done using the Xpert Tube Fill platform. The 
sensitivity and specificity compared to the composite reference standard were 15.0% and 100%; 
23.1% and 100% compared to first respiratory culture and 37.5% and 100.0% compared to the first 
respiratory Xpert (Table 3.8). The PPV was 100.0% for all reference standards whilst the NPV was the 
lowest for the composite reference standard at 63.0% and increased to 78.3% and 89.1% for the first 
respiratory culture and Xpert respectively. No indeterminate results were observed (0.0%). 
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Table 3.8. Method 6 Results summary 
Method 6: 
Lyophilisation + 




First Respiratory  
Culture 
First Respiratory  
Xpert 
Result POSITIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NEGATIVE 
POSITIVE 3 0 3 0 3 0 
NEGATIVE 17 29 10 36 5 41 
INDETERMINATE 0 0 0 0 0 0 
TOTAL 20 29 13 36 8 41 
Sensitivity 15.0 23.1 37.5 
Specificity 100.0 100.0 100.0 
 
3.2 Indeterminate rates 
 
The error rates for all methods are summarised in Figure 3.2. The FluoroType detection platform from 
Method 4 and Method 5 showed the highest indeterminate rates and the lowest indeterminate rates 
were seen in Methods 1, 3 and 6 respectively. 
 
 
Figure 3.2. Indeterminate rates for all methods 
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3.3 Overview of results 
 
In our setting, any child with suspected PTB would have at least one GA specimen, or ES in older 
children, tested by routine smear, culture and Xpert MTB/RIF (NHLS Tygerberg). We therefore 
compare the performance of the various index methods compared to the first respiratory culture (gold 
standard) result (Table 3.9). 
Table 3.9. Summary of method sensitivities as compared to the secondary reference standard (First 
respiratory culture) and indeterminate rates 
 
Method Sample Size Sensitivity Specificity 
Indeterminate 
Rate Detection Platform 
A n = 166 47.1% 97.8% 10.3% Xpert MTB/RIF 
B n = 196 45.8% 98.2% 3.4% Xpert MTB/RIF 
1 n = 13 40.0% 100% 0.0% Xpert Tube Fill 
2 n = 31 0.0% 70.4% 6.3% Xpert Tube Fill 
3 n = 63 44.4% 86.7% 0.0% Xpert Tube Fill 
4 n = 8 Not Calculated* 
Not 
Calculated* 75.0% FluoroType 
5 n = 33 75.0% 63.6% 42.4% FluoroType 
6 n = 49 23.1% 100% 0.0% Xpert Tube Fill 
*Sensitivity and specificity not calculated due to small numbers of specimens tested  
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Chapter 4: Discussion 
 
Stool is an attractive alternative specimen type for the laboratory diagnosis of TB in paediatric 
patients. Previous studies have shown that the TB bacilli can remain intact and survive the passage 
through the digestive system (88). The aim of the study was to evaluate the diagnostic utility of stool 
specimens using different protocols for the molecular detection of MTB in children investigated for 
suspected intrathoracic TB with or without extrathoracic TB.  
The study was divided into two sections: firstly, to determine the diagnostic performance of the Xpert 
MTB/RIF assay on raw and decontaminated stool specimens; and secondly, to determine whether 
including DNA extraction steps from raw and/or lyophilised specimens would improve performance 
of the molecular assays. 
Evaluation of new diagnostic methods for paediatric TB is complex as the reference standard (liquid 
culture) has poor sensitivity for paucibacillary TB (89). To improve on the reference standard, multiple 
respiratory specimens were collected by the study team and analysed by Xpert and culture. Although 
this strategy increases the number of cases confirmed bacteriologically, it also creates an unfair 
comparison for the index diagnostic strategy (molecular analysis of stool). Comparing the performance 
of Xpert and other molecular tests on a single stool specimen vs. the composite respiratory reference 
standard (up to 6 specimens) is biased and not a reflection of the current diagnostic practice.  
In the initial phase of the study, stool specimens were collected from children for smear microscopy, 
liquid culture and Xpert MTB/RIF testing (Method A). Smear microscopy and liquid culture results were 
analysed in a larger ongoing cohort study (Walters E, unpublished data) and will not be discussed here. 
However, culture contamination rates were high. Stool contains many microorganisms forming part 
of the normal flora. A high stool culture contamination rate (greater than the generally accepted rate 
of 5-8% for liquid culture) compared to respiratory specimens was also observed in other stool studies 
(79,90,91). Smear microscopy and liquid culture were therefore discontinued and subsequent stool 
specimens were processed for direct Xpert MTB/RIF testing only, according to a study-specific protocol 
involving centrifugation and concentration steps (Method B). The protocol for the direct detection of 
MTB from stool (Method B) mainly focused on the removal of large particulate matter and possible 
PCR-inhibitors by centrifugation and buffered wash-steps while attempting to preserve a detectable 
amount of MTB DNA as well as its integrity. Method A used the stool supernatants for 
decontamination after the larger stool particles had been allowed to settle (gravitational settling) 
where method B used a brief centrifugation step (mechanical settling) to settle these particulates. The 
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supernatants from the gravitationally settled samples in Method A could have contained more PCR 
inhibitors and perhaps some unsettled particulates. 
Individually, Method A detected MTB DNA in 11/195 (5.6%) participants, while Method B detected 
14/208 (6.7%) from stool specimens tested on the Xpert MTB/RIF platform. The relatively wide range 
of starting stool mass for both protocols, 0.3 g-5 g depending on the amount of stool received from a 
participant, reduces the reproducibility of the protocols. In addition, both methods require 
centrifugation, making them impractical for implementation in most high-burdened settings and 
limiting the point-of-care application for the Xpert MTB/RIF assay. 
The Xpert MTB/RIF assay on decontaminated and raw stool specimens (Method A and B) targeted 
intact bacilli (viable or non-viable) and showed a combined sensitivity of 45.8% - 47.1% (n = 403) 
compared to the first respiratory culture. Published data on the stool Xpert MTB/RIF assay report 
sensitivity between 47.1% - 100% compared to culture of up to 2 respiratory specimens (79–82). 
However, these studies only included small numbers of bacteriologically confirmed patients. When 
only considering the 2 larger studies (n = 267 and n = 115), the sensitivity range was narrower at 47.1% 
- 68.8% compared to respiratory specimen culture (80,81). This is similar to our finding, confirming 
the low sensitivity of Xpert MTB/RIF detection from stool specimens. 
The indeterminate rate using intact bacilli as a target was 10.3% for Method A, but decreased to 3.4% 
when the decontamination step was omitted in Method B. The increased indeterminate rate in 
Method A may have been due to increased Xpert inhibition resulting from the concentration of the 
specimen into a sediment (following the decontaminating procedure) and resuspending into 3 ml 
phosphate buffer and aspirating 1 ml for Xpert, compared to Method B where 1 ml was aspirated from 
the middle layer of post-centrifuged stool/phosphate buffer supernatants (10 ml). 
The range of specificity for both methods A and B against the CRS was 97.9 – 100%, while against the 
secondary reference standard the specificity was lower at 97.8% – 98.2%. Specificity below 100% may 
suggest false positive results for stool Xpert or may indicate that stool Xpert confirmed additional 
cases not detected on respiratory specimens. When considering the secondary reference standard, 
the specificity is lower because the reference standard itself missed cases detected on Xpert or culture 
of respiratory specimens other than the first one collected (2 for method A and 3 for method B). All 5 
cases were positive on stool Xpert. Only one case was negative on all respiratory specimens (by both 
culture and Xpert) but positive on stool Xpert by method A. The child was diagnosed with TB based on 
clinic-epidemiological and radiological evidence and is therefore likely to have represented a true 
positive stool Xpert. In all cases, respiratory and stool specimens were collected before treatment 
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initiation.  One participant for Method B had positive results on Xpert of both respiratory and stool 
specimens but was negative on all cultures. The child had had a previous episode of TB, but presented 
with new imaging features of neurotuberculosis and a worsening chest radiograph suggestive of active 
TB. Although it is debatable whether the chest radiology was indeed active TB, magnetic resonance 
imaging of the brain showed tuberculomas. The positive respiratory and stool Xpert, with negative 
respiratory cultures, may suggest that residual MTB DNA was present in respiratory secretions, and 
may not necessarily have indicated active pulmonary TB. However, the tuberculomas suggest active 
TB disease.  In summary, our results suggest that stool Xpert may have an incremental diagnostic value 
over the reference standard (92). 
Due to the high enzymatic content of intestinal secretions within stool specimens, it was hypothesised 
that the low sensitivity obtained with Method A and B may be due to the gastric environment 
degrading intact bacilli. Therefore, it was decided to extract DNA in an attempt to capture whole 
(intracellular) and extracellular MTB DNA fragments, thereby increasing the likelihood of reaching the 
limit of detection of the Xpert MTB/RIF assay (10). 
DNA was extracted manually from direct raw stool specimens (Method 1 and 2), and tested on the 
Xpert Tube Fill assay. This novel Xpert protocol was used to bypass the internal washing and DNA 
extraction steps within the GeneXpert cartridge. The sensitivities for Method 1 and 2 compared to the 
first respiratory culture were 40.0% and 0.0% respectively. Even though the numbers are too small for 
definitive conclusions (n = 13 and n = 32), it is evident that the sensitivity of MTB detection did not 
improve using these methods. Method 2 did however detect 8 positive signals with a low specificity 
of 70.4%, suggesting the possibility of false positive results. From the suspected false positives, only 
3/8 participants were started on antituberculosis treatment. While the indeterminate rate (6.3%) for 
Method 2 was similar to that seen in Method A and Method B, both indeterminate results were Xpert 
Tube Fill loading errors with insufficient remaining specimen to repeat the tests.  
A major challenge of processing stool specimens for all methods was the variability in stool 
consistencies and following the same protocol regardless of water content i.e. liquid (diarrhoeic) or 
solid (constipated) stool specimens. Due to the difficulty in obtaining a reproducible starting mass for 
the DNA protocols, it was hypothesised that removing the water from the stool by lyophilisation would 
allow for easy-to-work-with specimen and in turn possibly concentrate any intact or extracellular MTB 
present in the specimen.  
From published literature, lyophilisation has demonstrated an increased yield, and better quality of 
DNA for PCR-based studies using stool specimens obtained from pigs (93). Human studies looking at 
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other enteropathogens have also shown that lyophilisation significantly increases PCR-based 
detection of microorganisms from diarrheic stool specimens (94). From our own initial serial dilution 
experiments, we demonstrated that MTB DNA could be detected successfully from lyophilised stool 
specimens confirming that the DNA can remain intact following lyophilisation.  
Overall, DNA extraction from lyophilised stool specimens (Methods 3-6) detected 14/63, 2/8, 10/33 
and 3/49 instrument positive results on the respective detection platforms. Lyophilisation prior to 
manual DNA extraction and detection by Xpert Tube Fill (Method 3) showed a sensitivity of 44.4% 
compared to the first respiratory culture. The specificity of 86.7% suggested false positive results. 
However, 5/6 participants positive on stool but negative on culture/Xpert of respiratory specimens 
were started on antituberculosis treatment (after specimen collection). A second detection platform, 
the HAIN FluoroType assay, was considered as an alternative to the Xpert Tube Fill. There are no 
published data on the use of the automated FluoroType assay using stool specimens. Sputum data 
from adults, have reported a sensitivity of 100% for the FluoroType MTB for smear-positive 
participants, but only 56.3% for smear-negative participants from a low-incidence setting (84). 
Detection of MTB DNA using the FluoroType assay from manually extracted DNA (Method 4) had an 
extremely high indeterminate rate of 75.0%. Although only a small number of specimens were tested 
by this method, due to the large costs involved per specimen and the high indeterminate rate, a 
different DNA extraction method was used. The HAIN GenoXtract DNA extraction protocol was tested 
in combination with the FluoroType assay. 
The GenoXtract was used for DNA extraction from lyophilised stool specimens (Method 5). This 
method showed a sensitivity 75.0% when compared to the first respiratory culture. Although the low 
specificity of 63.6% suggested false positives, 3/4 of these participants were started on 
antituberculosis treatment. However, the indeterminate rate remained very high at 42.4%. Having 
concluded that the high indeterminate rate was due to the FluoroType detection assay, DNA extracted 
by GenoXtract from lyophilised stool specimens was tested on the Xpert Tube Fill detection platform 
(Method 6). The Xpert Tube Fill had a sensitivity of 23.1% compared to the first respiratory culture. 
The specificity however was the highest of all the methods tested at 100% (n = 49).  
A limitation of this study was that no direct comparisons could be made between methods as the 
different methods were not assessed in parallel on the same participants. A further limitation is the 
choice of reference standard. There is no established protocol for MTB detection in stool specimens, 
which could serve as an adequate reference for the novel detection methods presented in this thesis. 
Respiratory specimen mycobacteriology was therefore chosen as the most objective microbiological 
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standard available. Although it is established that both Xpert and culture are imperfect diagnostic tests 
for paediatric TB, due to their relatively low sensitivity to confirm paucibacillary TB, comparing our 
stool methods to clinical reference standards would require complex clinical analyses which are 
beyond the scope of this work. However, using both a CRS which was inclusive of all mycobacteriology 
results from respiratory specimens, and a secondary reference which constituted a fairer comparison, 
enabled us to better explain which stool protocols had low specificity due to the reference being less 
sensitive than the index test. We were able to identify which protocols had an incremental value over 
the reference test, and which protocols resulted in possible false positive results. 
In summary, we were not able to develop a diagnostic protocol that could detect MTB from paediatric 
stool samples with sufficient sensitivity. Direct Xpert MTB/RIF on stool without prior decontamination 
was the protocol with the best results for both sensitivity/specificity and invalid rate. In addition, direct 
stool Xpert detected additional cases not identified by the secondary reference standard. Some stool 
Xpert protocols published after this work was completed have demonstrated better sensitivity than 
our methods and warrant further study and validation in larger clinical cohorts (80,83). Although the 
Fluorotype platform demonstrated the best sensitivity, the high proportion of invalid results does not 
make this assay suitable for clinical application. Conversely, methods which demonstrated high 
specificity had sensitivity which was too low for clinical use.   
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Chapter 5: Conclusion 
 
Stool specimens can easily be collected in routine settings as an alternative specimen type for the 
diagnosis and/or confirmation of paediatric TB. Lyophilisation can be used to concentrate any type of 
stool specimen without severely affecting DNA integrity. MTB DNA can be successfully isolated from 
stool specimens and can subsequently be detected by the HAIN FluoroType, Xpert MTB/RIF and Xpert 
Tube Fill molecular detection platforms. The availability of more sensitive molecular detection tools 
could possibly increase the utility of using stool specimens for rapid TB diagnosis in children. Given the 
current lack of an optimised processing method for the detection of TB from stool specimens, further 
research is required for stool to become a quality, reliable and minimally invasive specimen type for 
TB diagnosis. Stool processing methods are labour intensive and combined with the increased 
potential of containing PCR-inhibitors, careful processing strategies will need to be developed. 
Patients with previous TB will require special consideration before a confirmatory diagnosis can be 
made using only molecular techniques as specimens may contain residual MTB DNA and may result in 
false positive test results. The high rate of HIV and TB co-infection, and its impact on childhood 
mortality in high-burden settings, dictates the need for accurate, rapid and cost effective diagnostic 
strategies. 
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Buffers and reagents 
 
4% Sodium Bicarbonate solution (100 ml) 
NaHCO3 (Sodium bicarbonate) powder   4 g 
Distilled water       100 ml 
 
10x TE buffer (500 ml) 
1 M Tris (hydroxymethyl) aminomethane pH 8.0  50 ml 
0.5 M EDTA (Diaminoethane tetraacetic acid) pH 8.0 10 ml 
Distilled water      440 ml 
 
Autoclave (121 °C; 15 minutes) 
 
 
BBL OADC Middlebrook enrichment media 
Bovine albumin      50 g 
Dextrose      20 g 
Oleic Acid      0.6 g 
Catalase      0.03 g 
  
BBL PANTA  
Polymyxin B      6000 units 
Amphotericin B      600 µg 
Nalidixic acid      2.4 mg 
Trimethoprim      600 µg 
Azlocillin      600 µg 
 
NALC-NaOH-sodium citrate 
Prepared fresh daily 
 
NaOH 5%       50 ml 
0.1 M trisodium citrate 3H2O     50 ml 
NALC powder       0.5 g 
 
Dissolved into 900 ml distilled water for a sodium hydroxide concentration of 2.5% 
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Phosphate buffered saline (PBS) 
0.067M disodium phosphate (A): 
Sodium monohydrogen phosphate   9.47 g 
Distilled water      1000 ml 
 
0.067M monopotassium phosphate (B): 
Potassium dihydrophosphate    9.07 g 
Distilled water      1000 ml 
 




Biological safety cabinet    LAB&AIR 
Heating block      LASEC SA 
Centrifuge (Heraeus Varifuge F)    Thermo Fischer Scientific   
BACTEC MGIT 960 system    Becton Dickinson 
Light and fluorescent microscope   OlympusX41 
GenoXtract (HAIN)     NorDiag ASA 
BP 211 D scale (d = 0.01 mg)    Sartorius 
Water bath – (Memmert)    LASEC SA 
 
  





FastDNA® Spin for Soil Kit (MP biomedicals) Protocol 
 
1. Add 0.1 g sample (stool) to Lysing Matrix E Tube 
2. Add 978 µl Sodium Phosphate Buffer and 122 µl MT buffer 
3. Secure tubes in the Ribolyser Instrument and process for 2 x 40 seconds at speed 6.0 
4. Centrifuge Lysing Matrix E tube at 18,407xg for 15 minutes to pellet debris 
5. Transfer supernatant to clean 2 ml tube, add 250 µl PPS reagent and shake tube by hand 10 
times 
6. Centrifuge at 18,407xg for 5 minutes to pellet precipitate, transfer supernatant to clean 15 ml 
tube. Add 1 ml Binding Matrix suspension to the supernatant 
7. Invert by hand for 2 minutes to allow binding of DNA to matrix, Place tubes in rack for 3 
minutes to settle Silica Matrix 
8. Remove 500 µl supernatant and discard, resuspend Binding Matrix in remaining supernatant 
and transfer 700 µl to a SPIN™ Filter and centrifuge at 18,407xg for 1 minute. Empty the catch 
tube and add remaining supernatant to the SPIN™ Filter and spin again. 
9. Add 500 µl SEWS-M to the SPIN™ Filter and gently resuspend the pellet using pipette tip 
(ensure ethanol has been pre-added to concentrated SEWS-M 
10. Centrifuge at 18,407xg for 1 minute; discard the flow through and any SEWS-M which did not 
pass through the matrix. Centrifuge for 2 minutes to remove residual SEWS-M wash solution 
11. Remove SPIN™ Filter and place in a new Catch Tube. Air dry for 5 minutes at room 
temperature 
12. Add 200 µl* DES (DNA/Pyrogen Free Water) to the binding matrix and gently stir with a finger 
flick to resuspend the silica. Incubate for 5 minutes at 55°C 
13. Centrifuge at 18,407xg for 1 minute to transfer eluted DNA to the catch tube 
* Protocol suggested 100 µl DES was increased to 200 µl to accommodate downstream protocols. 
  





QIAamp® Fast DNA Stool Mini Kit protocol 
Isolation of DNA from stool for pathogen detection 
1. Weigh 180-220 mg* stool in a 2 ml microcentrifuge tube and place tube on ice 
2. Add 1 ml InhibitEX buffer to each stool specimen, vortex continuously for 1 minute or until 
the stool specimen is thoroughly homogenised 
3. Heat the suspension for 5 minutes at 95°C**, vortex for 15 seconds 
4. Centrifuge specimen for 1 minute to pellet stool particles 
5. Pipet 15 µl Proteinase K into a new 1.5 ml microcentrifuge tube 
6. Pipet 200 µl supernatant from step 4 into the 1.5 ml microcentrifuge tube 
7.  Add 200 µl Buffer AL and vortex for 15 seconds. (Do NOT add Buffer AL directly to the 
Proteinase K) 
8. Incubate at 70°C for 10 minutes 
9. Add 200 µl of ethanol (96-100%) to the lysate, mix by vortexing 
10. Carefully apply 600 µl lysate from step 9 to the QIAamp spin column. Close the cap and 
centrifuge for 1 minute. Place the QIAamp spin column in a new 2 ml collection tube and 
discard the collection tube containing the filtrate 
11. Carefully open the QIAamp spin column and add 500 µl Buffer AW1. Centrifuge for 1 minute. 
Place QIAamp spin column in a new 2 ml collection tube and discard the collection tube 
containing the filtrate 
12. Carefully open the QIAamp spin column and add 500 µl Buffer AW2. Centrifuge for 3 minute. 
Discard the collection tube and the filtrate 
13. Place QIAamp spin column in a new 2 ml collection tube. Centrifuge for 3 minutes 
14. Transfer the QIAamp spin column in a new labelled 1.5 ml microcentrifuge tube. Pipette 200 
µl Buffer ATE directly onto the QIAamp membrane. Incubate for 1 minute at room 
temperature. Centrifuge for 1 minute to elute DNA 
* For lyophilised stool specimens 100 mg was used as starting material 
** The lysis temperature was increased from 70°C to 95°C for difficult to lyse cells (Gram-positive 
bacteria) 





GenoXtract Stool Extraction Kit VER 2.0 (HAIN) Protocol 
Kit for automated extraction of DNA from stool samples and rectal smears using the GenoXtract 
extraction instrument 
Preparation of stool specimens 
1. Using a swab, remove approximately 100 mg of stool specimen 
2. Elute swab for 10 seconds with 1 ml Stool Stabilizer into a 2 ml screw cap tube 
3. Vortex the specimen on a VV3 vortex at maximum speed for 5 minutes 
4. Centrifuge at 5000xg for 4 minutes in a standard table top centrifuge 
5. Transfer 500 µl of the supernatant to a 2 ml screw cap tube 
Preparation and start of GenoXtract instrument 
1. Assemble tips and pumps 
2. Turn on instrument and press “CONTINUE” after initialisation press “START PROTOCOL” 
3. Select protocol “GXT_Stool_DNA_V2” from the protocol list 
4. Select 200 µl as elution volume 
5. Mount required number of pump-tip units onto instrument; Press “OK” 
6. Open the required amount of foil covered Reagent Cartridges by rolling the Piercing Tool 
backwards and forwards several times with sufficient pressure. Ensure that all the wells are 
clearly opened 
7. Promptly load the opened Reagent Cartridges to the GenoXtract rack; Press “OK” 
8. Place specimen tubes from step 5 of preparation of stool specimens in corresponding position 
in the GenoXtract rack; Press “OK”   
9. Place required number of sterile 1.5 ml screw cap tubes for eluate in corresponding position 
in the GenoXtract rack; Press “OK”   
10. Close the door; Press “START” 
When the protocol is complete the touch-screen confirms that the run was successful. The eluate can 
be removed and is now ready for amplification. 
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Reagent Cartridge (GenoXtract Stool DNA) 
Well 1: empty (located in the heating block in the GenoXtract) 
Well 2: 2600 µl Elution buffer 
Well 3: 2600 µl Water 
Well 4: 2600 µl Water 
Well 5: 900 µl Wash Buffer II (65-80% ethanol) 
Well 6: 2500 µl Wash Buffer I (70-96% 2-propanol) 
Well 7: empty 
Well 8: 300 µl Magnetic Bead Solution 
Well 9: Empty 
Well 10: Empty 
Well 11: 1600 µl Lysis Buffer (40-55% guanidine thiocyanate, 10-20% triton X-100) 
Well 12: 500 µl (70-96% 2-proponol) 
Stool Stabilizer contains 15-20% ammonium chloride, 1-5% cetrimonium bromide 
  





FluoroType® MTB protocol 
Molecular Genetic Assay for detection of the MTBC from patient specimens using the FluoroCycler® 
Instrument. 
DNA Extraction 
For automated DNA extraction from patient specimens, the GenoXtract instrument in combination 
with the GXT Stool Extraction kit can be used (Appendix E).  
Amplification and detection 
All reagents required for amplification such as polymerase and primers are included in the 
amplification Mixes A and B (AM-A and AM-B) and are optimized for this test.  
1. After thawing, stir AM-A and AM-B carefully and spin down AM-A 
2. Prepare for each specimen: 3 µl AM-A 
7 µl AM-B 
6 µl DNA solution 
Final Volume: 16 µl 
3. Prepare a master mix containing AM-A and AM-B and mix carefully (Do NOT vortex) 
4. Aliquot 10 µl of master mix into each PCR tube 
5. Add 6 µl DNA solution in a separate area to each aliquot 
6. Switch on the FluoroCycler®, start the Fluoro-Software (version 1.0.0 or higher) on the 
connected computer 
7. Select the IVD mode and proceed as described in operator’s manual 
8. Starting at position 1 (leftmost position) place the prepared specimens in the FluoroCycler®; 
If less than 12 specimens, add an empty reaction tube in position 12 (rightmost position) to 
ensure proper closure of heating lid 
9. Select the “FluoroMicrobial1 PCR” protocol from the “Protocol” page of the Fluoro-Software 
10. Enter detailed specimen information on the “Samples” page 
11. Choose “FT_MTB” as test  
12. Start the run  
 





General laboratory flow diagram (overview of NALC/NaOH processing) 
 





GeneXpert MTB/RIF protocol 
 
Procedure – Sputum Sediments 
Note: Do not accept specimens with obvious food particles or other solid particulates. 
Note: Process only as many samples at one time as there are modules available to run the test on the 
GeneXpert Dx System. 
Guidelines for handling TB should be closely followed. 
Phosphate/H2O buffer can be tested using Xpert MTB/RIF. Once the resuspension is prepared for 
standard laboratory smear or culture tests, ensure at least 0.5 ml of resuspended sediment is available 
to run Xpert MTB/RIF. 
 
1. Label each Xpert MTB/RIF cartridge with the sample ID. (Write on the sides of the cartridge or 
affix ID label.) 
2. Transfer at least 0.5 mL of the total resuspension pellet to a conical, screw-capped tube for 
the Xpert MTB/RIF using a sterile 
3. Store re-suspended sediments at 2–8 °C if they are not immediately processed for Xpert 
MTB/RIF. Do not store for more than 12 hours 
4. Add 1.5 ml of Xpert MTB/RIF Sample Reagent (SR) to 0.5 mL (Ratio 3:1) of resuspended 
sediment sample using a sterile transfer pipette and shake vigorously 10 – 20 times. Note: 
One back-and-forth movement is a single shake* 
5. Incubate the specimen for 15 minutes at room temperature. At one point between 5 and 10 
minutes of the incubation, again shake the specimen vigorously 10 – 20 times. Samples should 
be liquefied with no visible clumps of sputum. Particulate matter may exist that is not part of 
the sample 
* In this study we used 2.0 ml Sample reagent and 1.0 ml of resuspended specimen ensuring that 
the ratio of 3:1 was maintained.  
  




SANAS accreditation for NHLS TB laboratory 
  








Example of specimen transport form including temperatures 
 




Correspondence with Cepheid regarding sample volume added to the Xpert MTB/RIF 
assay 
 




Infection control for respiratory specimen collection 
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